Cellular stress responses, hormetic phytochemicals and vitagenes in aging and longevity

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1822, Issue 5, 2012, Pages 753-783

  Calabrese, Vittorio ^a,f   Cornelius, Carolin ^a   Dinkova Kostova, Albena T ^b,c   Iavicoli, Ivo ^d   Di Paola, Rosanna ^e   Koverech, Aleardo ^g   Cuzzocrea, Salvatore ^e,f,i   Rizzarelli, Enrico ^a,f   Calabrese, Edward J ^h  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CATHOLIC UNIVERSITY   (Italy)

^e UNIVERSITY OF MESSINA   (Italy)

^f Interuniversity Consortium INBB   (Italy)

^g Sigma Tau SpA   (Italy)

^h UNIVERSITY OF MASSACHUSETTS   (United States)

ⁱ IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

Author keywords

Antioxidant; Cellular stress response; Hormesis; Mitochondria; Redox signaling; Vitagene

Indexed keywords

ADENOSINE TRIPHOSPHATE; FREE RADICAL; HEAT SHOCK PROTEIN; HEME OXYGENASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOCHONDRIAL DNA; REACTIVE OXYGEN METABOLITE;

AGING; ANTIOXIDANT ACTIVITY; AUTOPHAGY; BIOENERGY; CALORIC RESTRICTION; CELL AGING; CELL DEATH; CELL FISSION; CELL FUNCTION; CELL FUSION; CELL SURVIVAL; CELLULAR STRESS RESPONSE; DNA DAMAGE; ENDOSYMBIOSIS; EUKARYOTIC CELL; GENE; GLUCOSE METABOLISM; HORMESIS; LONGEVITY; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; MUTAGENICITY; NEUROPROTECTION; NITROSATIVE STRESS; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; SUMOYLATION; UBIQUITINATION; VITAGENE;

AGING; HORMESIS; HUMANS; LONGEVITY; OXIDATIVE STRESS;

EID: 84858153162     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2011.11.002     Document Type: Review

References (545)

1. Rogina B., Helfand S.L. Sir2 mediates longevity in the fly through a pathway related to calorie restriction. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:15998-16003.
2. Wood J.G., Rogina B., Lavu S., Howitz K., Helfand S.L., Tatar M., Sinclair D. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 2004, 430:686-689.
3. Hallows W.C., Albaugh B.N., Denu J.M. Where in the cell is SIRT3? Functional localization of an NAD+-dependent protein deacetylase. Biochem. J. 2008, 411:11-13.
4. Hursting S.D., Lavigne J.A., Berrigan D., Perkins S.N., Barrett J.C. Calorie restriction, aging, and cancer prevention: mechanisms of action and applicability to humans. Annu. Rev. Med. 2003, 54:131-152.
5. Saunders L.R., Verdin E. Cell biology. Stress response and aging. Science 2009, 323:1021-1022.
6. Donmez G., Guarente L. Aging and disease: connections to sirtuins. Aging Cell 2010, 9:285-290.
7. Guarente L., Partridge L., Wallace D.C. Molecular Biology of Aging 2008, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
8. Schwer B., Verdin E. Conserved metabolic regulatory functions of sirtuins. Cell Metab. 2008, 7:104-112.
9. Ozden O., Park S.H., Kim H.S., Jiang H., Coleman M.C., Spitz D.R., Gius D. Acetylation of MnSOD directs enzymatic activity responding to cellular nutrient status or oxidative stress. Aging 2011, 2011(3):102-107.
10. Deribe Y.L., Pawson T., Dikic I. Post-translational modifications in signal integration. Nat. Struct. Mol. Biol. 2010, 17:666-672.
11. Grahnert A., Grahnert A., Klein C., Schilling E., Wehrhahn J., Hauschildt S. NAD+: a modulator of immune functions. Innate Immun. 2010, 17:212-233.
12. Imai S. Nicotinamide phosphoribosyltransferase (Nampt): a link between NAD biology, metabolism, and diseases. Curr. Pharm. Des. 2009, 15:20-28.
13. Gallí M., Van Gool F., Leo O. Sirtuins and inflammation: friends or foes?. Biochem. Pharmacol. 2011, 81:569-576.
14. Andreou A.M., Tavernarakis N. SUMOylation and cell signaling. Biotechnol. J. 2009, 4:1740-1752.
15. Calabrese V., Scapagnini G., Giuffrida Stella A.M., Bates T.E., Clark J.B. Mitocondrial involvement in brain function and dysfunction: relevance to aging, neurodegenerative disordes and longevity. Neurochem. Res. 2001, 26:739-764.
16. Druzhyna N.M., Wilson G.L., LeDoux S.P. Mitochondrial DNA repair in aging and disease. Mech. Ageing Dev. 2008, 129:383-390.
17. Hamm-Alvarez S., Cadenas E. Mitochondrial medicine and mitochondrion-based therapeutics. Adv. Drug Deliv. Rev. 2009, 60:1437-1438.
18. Calabrese V., Cornelius C., Dinkova-Kostova A.T., Calabrese E.J., Mattson M.P. Cellular stress responses, the hormesis paradigm and vitagenes: novel tragets for therapeutic intervention in neurodegenerative disorders. Antioxid. Redox Signal. 2010, 13:1763-1811.
19. Yap L.P., Garcia J.V., Han D., Cadenas E. The energy-redox axis in aging and age-related neurodegeneration. Adv. Drug Deliv. Rev. 2009, 61:1283-1298.
20. Harman D. Aging: a theory based on free radical and radiation chemistry. J. Gerontol. 1956, 11:298-300.
21. Harman D. The biologic clock: the mitochondria?. J. Am. Geriatr. Soc. 1972, 20:145-147.
22. Calabrese V., Guagliano E., Sapienza M., Panebianco M., Calafato S., Puleo E., Pennisi G., Mancuso C., Butterfield D.A., Stella A.G. Redox regulation of cellular stress response in aging and neurodegenerative disorders: role of vitagenes. Neurochem. Res. 2007, 32:757-773.
23. Schapira A.H. Primary and secondary defects of the mitochondrial respiratory chain. J. Inherit. Metab. Dis. 2002, 25:207-214.
24. Calabrese V., Scapagnini G., Colombrita C., Ravagna A., Pennisi G., Giuffrida stella A.M., Galli F., Butterfield D.A. Redox regulation of the heat shock protein expression in aging and neurodegenerative disorders associated with oxidative stress: a nutritional approach. Amino Acids 2003, 25:437-444.
25. Calabrese V., Cornelius C., Mancuso C., Pennisi G., Calafato S., Bellia F., Bates T.E., Giuffrida Stella A.M., Schapira T., Dinkova Kostova A.T., Rizzarelli E. Cellular stress response: a novel target for chemoprevention and nutritional neuroprotection in aging, neurodegenerative disorders and longevity. Neurochem. Res. 2008, 33:2444-2471.
26. Tonon C., Lodi R. Idebenone in Friedreich's ataxia. Expert Opin. Pharmacother. 2008, 9:2327-2337.
27. Petrosillo G., Matera M., Casanova G., Ruggiero F.M., Paradies G. Mitochondrialdysfunction in rat brain with aging involvement of complex I, reactive oxygen species and cardiolipin. Neurochem. Int. 2008, 53:126-131.
28. Ames B.N., Liu J. Delaying the mitochondrial decay of aging with acetylcarnitine. Ann. N. Y. Acad. Sci. 2004, 1033:108-116.
29. Hempenstall S., Picchio L., Mitchell S.E., Speakman J.R., Selman C. The impact of acute caloric restriction on the metabolic phenotype in male C57BL/6 and DBA/2 mice. Mech. Ageing Dev. 2010, 131:111-118.
30. Mattson M.P. Dietary factors, hormesis and health. Ageing Res. Rev. 2008, 7:43-48.
31. Ristow M., Zarse K. How increased oxidative stress promotes longevity and metabolic health: the concept of mitochondrial hormesis (mitohormesis). Exp. Gerontol. 2010, 45:410-418.
32. Ristow M., Zarse K., Oberbach A., Klöting N., Birringer M., Kiehntopf M., Stumvoll M., Kahn C.R., Blüher M. Antioxidants prevent health-promoting effects of physical exercise in humans. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:8665-8670.
33. Ristow M., Schmeisser S. Extending life span by increasing oxidative stress. Free Radic. Biol. Med. 2011, 51:327-336.
34. Forquer I., Covian R., Bowman M.K., Trumpower B.L., Kramer D.M. Similar transition states mediate the Q-cycle and superoxide production by the cytochrome bc1 complex. J. Biol. Chem. 2006, 281:38459-38465.
35. Bilban M., Haschemi A., Wegiel B., Chin B.Y., Wagner O., Otterbein L.E. Heme oxygenase and carbon monoxide initiate homeostatic signaling. J. Mol. Med. 2008, 86:267-279.
36. Halliwell B. The wanderings of a free radical. Free Radic. Biol. Med. 2009, 46:531-542.
37. Calabrese V., Mancuso C., Calvani M., Rizzarelli E., Butterfield D.A., Giuffrida Stella A.M. Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity. Nat. Rev. Neurosci. 2007, 8:766-775.
38. Calabrese V., Cornelius C., Rizzarelli E., Owen J.B., Dinkova-Kostova A.T., Butterfield D.A. Nitric oxide in cell survival: a Janus molecule. Antioxid. Redox Signal. 2009, 11:2717-2739.
39. Wang W., Fang H., Groom L., Cheng A., Zhang W., Liu J., Wang X., Li K., Han P., Zheng M., Yin J., Wang W., Mattson M.P., Kao J.P., Lakatta E.G., Sheu S.S., Ouyang K., Chen J., Dirksen R.T., Cheng H. Superoxide flashes in single mitochondria. Cell 2008, 134:279-290.
40. McCord J.M. Superoxide dismutase in aging and disease: an overview. Methods Enzymol. 2002, 349:331-341.
41. Cho D.H., Nakamura T., Lipton S.A. Mitochondrial dynamics in cell death and neurodegeneration. Cell. Mol. Life Sci. 2010, 67:3435-3447.
42. Nakamura T., Cieplak P., Cho D.H., Godzik A., Lipton S.A. S-Nitrosylation of Drp1 links excessive mitochondrial fission to neuronal injury in neurodegeneration. Mitochondrion 2010, 10:573-578.
43. Gu Z., Nakamura T., Lipton S.A. Redox reactions induced by nitrosative stress mediate protein misfolding and mitochondrial dysfunction in neurodegenerative diseases. Mol. Neurobiol. 2010, 41:55-72.
44. Büeler H. Mitochondrial dynamics, cell death and the pathogenesis of Parkinson's disease. Apoptosis 2010, 15:1336-1353.
45. Knott A.B., Perkins G., Schwarzenbacher R., Bossy-Wetzel E. Mitochondrial fragmentation in neurodegeneration. Nat. Rev. Neurosci. 2008, 9:505-518.
46. Bonda D.J., Wang X., Perry G., Smith M.A., Zhu X. Mitochondrial dynamics in Alzheimer's disease: opportunities for future treatment strategies. Drugs Aging 2010, 27:181-192.
47. Gottlieb R.A., Carreira R.S. Autophagy in health and disease. 5. Mitophagy as a way of life. Am. J. Physiol. Cell Physiol. 2010, 299:C203-C210.
48. Rosca M.G., Lemieux H., Hoppel C.L. Mitochondria in the elderly: is acetylcarnitine a rejuvenator?. Adv. Drug Deliv. Rev. 2009, 61:1332-1342.
49. Borniquel S., García-Quintáns N., Valle I., Olmos Y., Wild B., Martínez-Granero F., Soria E., Lamas S., Monsalve M. Inactivation of Foxo3a and subsequent downregulation of PGC-1 alpha mediate nitric oxide-induced endothelial cell migration. Mol. Cell. Biol. Aug 2010, 30:4035-4044.
50. Piantadosi C.A. Carbon monoxide, reactive oxygen signaling, and oxidative stress. Free Radic. Biol. Med. 2008, 45:562-569.
51. Calabrese V., Cornelius C., Dinkova-Kostova A.T., Calabrese E.J. Vitagenes, cellular stress response, and acetylcarnitine: relevance to hormesis. Biofactors 2009, 35:146-160.
52. Piantadosi C.A., Carraway M.S., Babiker A., Suliman H.B. Heme oxygenase-1 regulates cardiac mitochondrial biogenesis via Nrf2-mediated transcriptional control of nuclear respiratory factor-1. Circ. Res. 2008, 103:1232-1240.
53. Azad M.B., Chen Y., Gibson S.B. Regulation of autophagy by reactive oxygen species (ROS): implications for cancer progression and treatment. Antioxid. Redox Signal. 2009, 11:777-790.
54. Nassif M., Matus S., Castillo K., Hetz C. Amyotrophic lateral sclerosis pathogenesis: a journey through the secretory pathway. Antioxid. Redox Signal. 2010, 13:1955-1989.
55. Madeo F., Eisenberg T., Kroemer G. Autophagy for the avoidance of neurodegeneration. Genes Dev. 2009, 23:2253-2259.
56. Fujioka Y., Noda N.N., Nakatogawa H., Ohsumi Y., Inagaki F. Dimeric coiled-coil structure of Saccharomyces cerevisiae Atg16 and its functional significance in autophagy. J. Biol. Chem. 2010, 285:1508-1515.
57. Jakubowicz-Gil J., Langner E., Wertel I., Piersiak T., Rzeski W. Temozolomide, quercetin and cell death in the MOGGCCM astrocytoma cell line. Chem. Biol. Interact. 2010, 188:190-203.
58. Li Q., Verma I.M. Nf-kappab regulation in the immune system. Nat. Rev. 2002, 2:725-734.
59. Silverman N., Maniatis T. Nf-kappab signaling pathways in mammalian and insect innate immunity. Genes Dev. 2001, 15:2321-2342.
60. Ghosh S., Hayden M.S. New regulators of nf-kappab in inflammation. Nat. Rev. 2008, 8:837-848.
61. Hayden M.S., Ghosh S. Shared principles in nf-kappab signaling. Cell 2008, 132:344-362.
62. Criswell T., Leskov K., Miyamoto S., Luo G., Boothman D.A. Transcription factors activated in mammalian cells after clinically relevant doses of ionizing radiation. Oncogene 2003, 22:5813-5827.
63. Janssens S., Tschopp J. Signals from within: the DNA-damage-induced nf-kappab response. Cell Death Differ. 2006, 13:773-784.
64. Peters R.T., Liao S.M., Maniatis T. Ikkepsilon is part of a novel pma-inducible ikappab kinase complex. Mol. Cell 2000, 5:513-522.
65. Shimada T., Kawai T., Takeda K., Matsumoto M., Inoue J., Tatsumi Y., Kanamaru A., Akira S. Ikk-i, a novel lipopolysaccharide-inducible kinase that is related to ikappab kinases. Int. Immunol. 1999, 11:1357-1362.
66. Chen Y., Yang L., Lee T.J. Oroxylin a inhibition of lipopolysaccharide-induced inos and cox-2 gene expression via suppression of nuclear factor-kappab activation. Biochem. Pharmacol. 2000, 59:1445-1457.
67. Pahan K., Sheikh F.G., Namboodiri A.M., Singh I. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J. Clin. Invest. 1997, 100:2671-2679.
68. Salvemini D., Mazzon E., Dugo L., Riley D.P., Serraino I., Caputi A.P., Cuzzocrea S. Pharmacological manipulation of the inflammatory cascade by the superoxide dismutase mimetic m40403. Br. J. Pharmacol. 2001, 132:815-827.
69. Pistritto G., Mancuso C., Tringali G., Perretti M., Preziosi P., Navarra P. The relative contribution of constitutive and inducible cyclooxygenase activity to lipopolysaccharide-induced prostaglandin production by primary cultures of rat hypothalamic astrocytes. Neurosci. Lett. 1998, 246:45-48.
70. Cuzzocrea S., Caputi A.P., Zingarelli B. Peroxynitrite-mediated DNA strand breakage activates poly (adp-ribose) synthetase and causes cellular energy depletion in carrageenan-induced pleurisy. Immunology 1998, 93:96-101.
71. Salgo M.G., Bermudez E., Squadrito G.L., Pryor W.A. Peroxynitrite causes DNA damage and oxidation of thiols in rat thymocytes [corrected]. Arch. Biochem. Biophys. 1995, 322:500-505.
72. Gutteridge J.M., Halliwell B. Antioxidants: molecules, medicines, and myths. Biochem. Biophys. Res. Commun. 2010, 393:561-564.
73. Salminen A., Kaarniranta K. Nf-kappab signaling in the aging process. J. Clin. Immunol. 2009, 29:397-405.
74. Dutta J., Fan Y., Gupta N., Fan G., Gelinas C. Current insights into the regulation of programmed cell death by nf-kappab. Oncogene 2006, 25:6800-6816.
75. Nakano H., Nakajima A., Sakon-Komazawa S., Piao J.H., Xue X., Okumura K. Reactive oxygen species mediate crosstalk between nf-kappab and jnk. Cell Death Differ. 2006, 13:730-737.
76. Hiona A., Leeuwenburgh C. Effects of age and caloric restriction on brain neuronal cell death/survival. Ann. N. Y. Acad. Sci. 2004, 1019:96-105.
77. Kim H.J., Kim K.W., Yu B.P., Chung H.Y. The effect of age on cyclooxygenase-2 gene expression: Nf-kappab activation and ikappabalpha degradation. Free Radic. Biol. Med. 2000, 28:683-692.
78. Helenius M., Hanninen M., Lehtinen S.K., Salminen A. Changes associated with aging and replicative senescence in the regulation of transcription factor nuclear factor-kappa b. Biochem. J. 1996, 318:603-608.
79. Cuthbertson D., Smith K., Babraj J., Leese G., Waddell T., Atherton P., Wackerhage H., Taylor P.M., Rennie M.J. Anabolic signaling deficits underlie amino acid resistance of wasting, aging muscle. FASEB J. 2005, 19:422-424.
80. Schmitz M.L., Mattioli I., Buss H., Kracht M. Nf-kappab: a multifaceted transcription factor regulated at several levels. Chembiochem 2004, 5:1348-1358.
81. Chen L.F., Greene W.C. Regulation of distinct biological activities of the nf-kappab transcription factor complex by acetylation. J. Mol. Med. 2003, 81:549-557.
82. Yeung F., Hoberg J.E., Ramsey C.S., Keller M.D., Jones D.R., Frye R.A., Mayo M.W. Modulation of nf-kappab-dependent transcription and cell survival by the sirt1 deacetylase. EMBO J. 2004, 23:2369-2380.
83. Adler A.S., Sinha S., Kawahara T.L., Zhang J.Y., Segal E., Chang H.Y. Motif module map reveals enforcement of aging by continual nf-kappab activity. Genes Dev. 2007, 21:3244-3257.
84. Burnett C., Valentini S., Cabreiro F., Goss M., Somogyvári M., Piper M.D., Hoddinott M., Sutphin G.L., Leko V., McElwee J.J., Vazquez-Manrique R.P., Orfila A.M., Ackerman D., Au C., Vinti G., Riesen M., Howard K., Neri C., Bedalov A., Kaeberlein M., Soti C., Partridge L., Gems D. Absence of effects of Sir2 overexpression on lifespan in C. elegans and Drosophila. Nature 2011, 477:482-485.
85. Yogev O., Goldberg R., Anzi S., Yogev O., Shaulian E. Jun proteins are starvation-regulated inhibitors of autophagy. Cancer Res. 2010, 70:2318-2327.
86. Morimoto R.I. Stress, aging, and neurodegenerative disease. N. Engl. J. Med. 2006, 355:2254-2255.
87. Morimoto R.I. Proteotoxic stress and inducible chaperone networks in neurodegenerative disease and aging. Genes Dev. 2008, 22:1427-1438.
88. Westerheide S.D., Anckar J., Stevens S.M., Sistonen L., Morimoto R.I. Stress-inducible regulation of heat shock factor 1 by the deacetylase SIRT1. Science 2009, 323:1063-1066.
89. Trott A., West J.D., Klaic L., Westerheide S.D., Silverman R.B., Morimoto R.I., Morano K.A. Activation of heat shock and antioxidant responses by the natural product celastrol: transcriptional signatures of a thiol-targeted molecule. Mol. Biol. Cell 2008, 19:1104-1112.
90. Moi P., Chan K., Asunis I., Cao A., Kan Y.W. Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:9926-9930.
91. Anckar J., Sistonen L. Heat shock factor 1 as a coordinator of stress and developmental pathways. Adv. Exp. Med. Biol. 2007, 594:78-88.
92. Morimoto R.I. Regulation of the heat shock transcriptional response: cross talk between a family of heat shock factors, molecular chaperones, and negative regulators. Genes Dev. 1998, 12:3788-3796.
93. Brignull H.R., Morley J.F., Morimoto R.I. The stress of misfolded proteins: C. elegans models for neurodegenerative disease and aging. Adv. Exp. Med. Biol. 2007, 594:167-189.
94. Rossi A., Trotta E., Brandi R., Arisi I., Coccia M., Santoro M.G. AIRAP: a new human Heat shock gene regulated by Heat shock factor 1. J. Biol. Chem. 2010, 285:13607-13615.
95. Batulan Z., Shinder G.A., Minotti S., He B.P., Doroudchi M.M., Nalbantoglu J., Strong M.J., Durham H.D. High threshold for induction of the stress response in motor neurons is associated with failure to activate HSF1. J. Neurosci. 2003, 23:5789-5798.
96. Calderwood S.K., Murshid A., Prince T. The shock of aging: molecular chaperones and the heat shock response in longevity and aging-a mini-review. Gerontology 2009, 55:550-558.
97. Lu M., Kim H.E., Li C.R., Kim S., Kwak I.J., Lee Y.J., Kim S.S., Moon J.Y., Kim C.H., Kim D.K., Kang H.S., Park J.S. Two distinct disulfide bonds formed in human heat shock transcription factor 1 act in opposition to regulate its DNA binding activity. Biochemistry 2008, 47:6007-6015.
98. Söti C., Csermely P. Aging cellular networks: chaperones as major participants. Exp. Gerontol. 2007, 42:113-119.
99. Söti C., Csermely P. Protein stress and stress proteins: implications in aging and disease. J. Biosci. 2007, 32:511-515.
100. Macario A.J., Conway de Macario E. Molecular chaperones: multiple functions, pathologies, and potential applications. Front. Biosci. 2007, 12:2588-2600.
101. Macario A.J., Conway de Macario E. Sick chaperones, cellular stress, and disease. N. Engl. J. Med. 2005, 353:1489-1501.
102. Csermely P., Söti C., Blatch G.L. Chaperones as parts of cellular networks. Adv. Exp. Med. Biol. 2007, 594:55-63.
103. Broadley S.A., Hartl F.U. The role of molecular chaperones in human misfolding diseases. FEBS Lett. 2009, 583:2647-2653.
104. Goloubinoff P., De Los Rios P. The mechanism of Hsp70 chaperones: (entropic) pulling the models together. Trends Biochem. Sci. 2007, 32:372-380.
105. Saibil H.R. Chaperone machines in action. Curr. Opin. Struct. Biol. 2008, 18:35-42.
106. Macario A.J., Conway de Macario E. Chaperonopathies by defect, excess, or mistake. Ann. N. Y. Acad. Sci. 2007, 1113:178-191.
107. Calabrese V., Cornelius C., Mancuso C., Lentile R., Stella A.M., Butterfield D.A. Redox homeostasis and cellular stress response in aging and neurodegeneration. Methods Mol. Biol. 2010, 610:285-308.
108. Hipkiss A.R. On why decreasing protein synthesis can increase lifespan. Mech. Ageing Dev. 2007, 128:412-414.
109. Sharma S.K., Christen P., Goloubinoff P. Disaggregating chaperones: an unfolding story. Curr. Protein Pept. Sci. 2009, 10:432-446.
110. Zhang K., Zhao T., Huang X., Liu Z.H., Xiong L., Li M.M., Wu L.Y., Zhao Y.Q., Zhu L.L., Fan M. Preinduction of HSP70 promotes hypoxic tolerance and facilitates acclimatization to acute hypobaric hypoxia in mouse brain. Cell Stress Chaperones 2009, 14:407-415.
111. Calabrese V., Giuffrida Stella A.M., Butterfield D.A., Scapagnini G. Redox regulation in neurodegeneration and longevity: role of the heme oxygenase and HSP70 systems in brain stress tolerance. Antioxid. Redox Signal. 2004, 6:895-913.
112. Delgado M., Varela N., Gonzalez-Rey E. Vasoactive intestinal peptide protects against beta-amyloid-induced neurodegeneration by inhibiting microglia activation at multiple levels. Glia 2008, 56:1091-1103.
113. Kakimura J., Kitamura Y., Takata K., Umeki M., Suzuki S., Shibagaki K., Taniguchi T., Nomura Y., Gebicke-Haerter P.J., Smith M.A., Perry G., Shimohama S. Microglial activation and amyloid-beta clearance induced by exogenous heat-shock proteins. FASEB J. 2002, 16:601-603.
114. Calabrese V., Mancuso C., Ravagna A., Perluigi M., Cini C., De Marco C., Butterfield D.A., Giuffrida Stella A.M. In vivo induction of heat shock proteins in the substantia nigra following L-DOPA administration is associated with increased activity of mitochondrial complex I and nitrosative stress in rats: regulation by glutathione redox state. J. Neurochem. 2007, 101:709-717.
115. Bellia F., Calabrese V., Guarino F., Cavallaro M., Cornelius C., De Pinto V., Rizzarelli E. Carnosinase levels in aging brain: redox state induction and cellular stress response. Antioxid. Redox Signal. 2009, 11:2759-2775.
116. Brown I.R. Heat shock proteins and protection of the nervous system. Ann. N. Y. Acad. Sci. 2007, 1113:147-158.
117. Calabrese V., Calafato S., Cornelius C., Mancuso C., Dinkova-Kostova A. Heme oxygenase: a master vitagene involved in cellular stress response. Enzymes and the Cellular Fight Against Oxidation 2008, 37-661. Research Signpost, Fort P.O., Trivandrum-695 023, Kerala, India, (2). A.M. Eleuteri (Ed.).
118. Maines M.D. The heme oxygenase system: a regulator of second messenger gases. Annu. Rev. Pharmacol. Toxicol. 1997, 37:517-554.
119. Calabrese V., Cornelius C., Mancuso C., Barone E., Calafato S., Bates T., Rizzarelli E., Kostova A.T. Vitagenes, dietary antioxidants and neuroprotection in neurodegenerative diseases. Front. Biosci. 2009, 14:376-397.
120. Schipper H.M. Heme oxygenase-1: role in brain aging and neurodegeneration. Exp. Gerontol. 2000, 35:821-830.
121. Stocker R., Yamamoto Y., McDonagh A.F., Glazer A.N., Ames B.N. Bilirubin is an antioxidant of possible physiological importance. Science 1987, 235:1043-1046.
122. Doré S., Takahashi M., Ferris C.D., Zakhary R., Hester L.D., Guastella D., Snyder S.H. Bilirubin, formed by activation of heme oxygenase-2, protects neurons against oxidative stress injury. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:2445-2450.
123. Mancuso C., Pani G., Calabrese V. Bilirubin: an endogenous scavenger of nitric oxide and reactive nitrogen species. Redox Rep. 2006, 11:207-213.
124. Scapagnini G., Colombrita C., Amadio M., D'Agata V., Arcelli E., Sapienza M., Quattrone A., Calabrese V. Curcumin activates defensive genes and protects neurons against oxidative stress. Antioxid. Redox Signal. 2006, 8:395-403.
125. Dennery P.A. Regulation and role of heme oxygenase in oxidative injury. Curr. Top. Cell. Regul. 2000, 36:181-199.
126. Maines M.D., Gibbs P.E.M. 30 some years of heme oxygenase: from a "molecular wrecking ball" to a "mesmerizing" trigger of cellular events. Biochem. Biophys. Res. Commun. 2005, 338:568-577.
127. Kapitulnik J., Maines M.D. Pleiotropic functions of biliverdin reductase: cellular signaling and generation of cytoprotective and cytotoxic bilirubin. Trends Pharmacol. Sci. 2009, 30:129-137.
128. Alam J., Cook J.L. How many transcription factors does it take to turn on the heme oxygenase-1 gene?. Am. J. Respir. Cell Mol. Biol. 2007, 36:166-174.
129. Nguyen T., Sherratt P.J., Pickett C.B. Regulatory mechanism controlling gene expression mediated by the antioxidant response element. Annu. Rev. Pharmacol. Toxicol. 2003, 43:233-260.
130. Panahian N., Yoshiura M., Maines M.D. Overexpression of heme oxygenase-1 is neuroprotective in a model of permanent middle cerebral artery occlusion in transgenic mice. J. Neurochem. 1999, 72:1187-1203.
131. McCoubrey W.K., Huang T.J., Maines M.D. Heme oxygenase-2 is a hemoprotein and binds heme through heme regulatory motifs that are not involved in heme catalysis. J. Biol. Chem. 1997, 272:12568-12574.
132. Calabrese V., Bates T.E., Mancuso C., Cornelius C., Ventimiglia B., Cambria M.T., Di Renzo L., De Lorenzo A., Dinkova-Kostova A.T. Curcumin and the cellular stress response in free radical-related diseases. Mol. Nutr. Food Res. 2008, 52:1062-1073.
133. Calabrese V., Perluigi M., Cornelius C., Coccia R., Di Domenico F., Mancuso C., Pennini G., Dinkova-Kostova A.T. Phenolics in aging and neurodegenerative disorders. Phenolic Compounds of Plant Origin and Health: The Biochemistry behind their Nutritional and Pharmacological Value 2009, 427-451. Wiley & Sons, New York. C.G. Fraga (Ed.).
134. Motterlini R., Foresti R., Bassi R., Calabrese V., Clark J.E., Green C.J. Endothelial Heme oxygenase-1 induction by hypoxia: modulation by inducible nitric oxide synthase (iNOS) and S-nitrosothiols. J. Biol. Chem. 2000, 275:13613-13620.
135. Motterlini R., Foresti R., Bassi R., Green C.J. Curcumin, an antioxidant and anti-inflammatory agent, induces heme oxygenase-1 and protects endothelial cells against oxidative stress. Free Radic. Biol. Med. 2000, 28:1303-1312.
136. Lim G.P., Yang F., Chu T., Chen P., Beech W., Teter B., Tran T., Ubeda O., Ashe K.H., Frautschy S.A., Cole G.M. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J. Neurosci. 2000, 20:5709-5714.
137. Yang F., Lim G.P., Begum A.N., Ubeda O.J., Simmons M.R., Ambegaokar S.S., Chen P.P., Kayed R., Glabe C.G., Frautschy S.A., Cole G.M. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. 2005, 280:5892-5901.
138. Li Y., Xu W., McBurney M.W., Longo V.D. SirT1 inhibition reduces IGF-I/IRS-2/Ras/ERK1/2 signaling and ptotects neurons. Cell Metab. 2008, 8:38-48.
139. Anand P., Nair H.B., Sung B., Kunnumakkara A.B., Yadav V.R., Tekmal R.R., Aggarwal B.B. Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochem. Pharmacol. 2010, 79:330-338.
140. Sandur S.K., Deorukhkar A., Pandey M.K., Pabón A.M., Shentu S., Guha S., Aggarwal B.B., Krishnan S. Curcumin modulates the radiosensitivity of colorectal cancer cells by suppressing constitutive and inducible NF-kappaB activity. Int. J. Radiat. Oncol. Biol. Phys. 2009, 75:534-542.
141. Kitamuro T., Takahashi K., Ogawa K., Udono-Fujimori R., Takeda K., Furuyama K., Nakayama M., Sun J., Fujita H., Hida W., Hattori T., Shirato K., Igarashi K., Shibahara S. Bach1 functions as a hypoxia-inducible repressor for the heme oxygenase-1 gene in human cells. J. Biol. Chem. 2003, 278:9125-9133.
142. Chou Y.H., Ho F.M., Liu D.Z., Lin S.Y., Tsai L.H., Chen C.H., Ho Y.S., Hung L.F., Liang Y.C. The possible role of heat shock factor-1 in the negative regulation of heme oxygenase-1. Int. J. Biochem. Cell Biol. 2005, 37:604-615.
143. Schipper H.M., Song W., Zukor H., Hascalovici J.R., Zeligman D. Heme oxygenase-1 and neurodegeneration: expanding frontiers of engagement. J. Neurochem. 2009, 110:469-485.
144. Schulz H. Uber Hefegifte. Pflugers Arch. Ges. Physiol. 1888, 42:517-541.
145. Calabrese E.J. Evidence that hormesis represents an "overcompensation" response to a disruption in homeostasis. Ecotoxicol. Environ. Saf. 1999, 42:135-137.
146. Mitchel R.E.J. Low doses of radiation reduce risk in vivo. Dose Response 2007, 5:1-10.
147. Lacassagne A., Buu-Hoi N.P., Rudali G. Induction of the carcinogenic action produced by a weakly carcinogenic hydrocarbon on a highly active carcinogenic hydrocarbon. Br. J. Exp. Pathol. 1945, 26:5-12.
148. Sykes P.J., Morley A.A., Hooker A.M. The pKZ1 recombination mutation assay: a sensitive assay for low dose studies. Dose Response 2006, 4:91-105.
149. Boreham D.R., Dolling J.A., Somers C., Quinn J., Mitchel R.E.J. The adaptive response and protection against heritable mutations and fetal malformation. Dose Response 2006, 4:317-326.
150. Mothersill C., Seymour C.B. Radiation-induced bystander effects and the DNA paradigm: an "out of field" perspective. Mutat. Res. 2006, 597:5-10.
151. Sakai K., Nomura T., Ina Y. Enhancement of bio-protective functions by low dose/dose-rate radiation. Dose Response 2006, 4:327-332.
152. Scott B.R., DiPalma J. Sparsely ionizing diagnostic and natural background radiations are likely preventing cancer and other genomic instability-associated diseases. Dose Response 2006, 5:230-255.
153. Redpath J.L. Suppression of neoplastic transformation in vitro by low doses of low LET radiation. Dose Response 2006, 4:302-308.
154. Calabrese E.J., Baldwin L.A. Chemical hormesis: its historical foundations as a biological hypothesis. Toxicol. Pathol. 1999, 27:195-216.
155. Calabrese E.J., Baldwin L.A. Radiation hormesis: its historical foundations as a biological hypothesis. Hum. Exp. Toxicol. 2000, 19:41-75.
156. Calabrese E.J., Baldwin L.A. Radiation hormesis: the demise of a legitimate hypothesis. Hum. Exp. Toxicol. 2000, 19:76-84.
157. Calabrese E.J., Baldwin L.A. The marginalization of hormesis. Hum. Exp. Toxicol. 2000, 19:32-40.
158. Calabrese E.J., Baldwin L.A. Ethanol and hormesis. Crit. Rev. Toxicol. 2003, 33:407-424.
159. Calabrese E.J. Hormesis. Encyclopedia of Quantitative Risk Assessment and Analysis 2008, 838-844. Wiley, Chichester. E. Melnick, B. Everitt (Eds.).
160. Calabrese E.J. The road to linearity: shy linearity at low doses became the basis for carcinogen risk assessment. Arch. Toxicol. 2009, 83:203-225.
161. Szabadi E. Model of 2 functionally antagonistic receptor populations activated by same agonist. J. Theor. Biol. 1977, 69:101-112.
162. Stebbing A.R.D. Effects of low metal levels on a clonal hydroid. J. Mar. Biol. Assoc. U.K. 1976, 56:977-994.
163. Luckey T.D. Radiation Hormesis 1992, CRC, Boca Raton.
164. Calabrese E.J., Baldwiw L.A. Tales of two similar hypothesis: the rise and fall of chemical and radiation hormesis. Hum. Exp. Toxicol. 2000, 19:85-97.
165. Calabrese E.J., Blain R. The occurrence of hormetic dose responses in the toxicological literature, the hormesis database: an overview. Toxicol. Appl. Pharmacol. 2005, 202:289-301.
166. Thong H.Y., Maibach H.I. Hormesis (biological effects of low level exposure (BELLE)) and dermatology. Dose Response 2008, 6:1-15.
167. Eaton D.L., Klaassen C.D. Principles of toxicology. Casarett & Doull's Essentials of Toxicology, Chap 2 2003, 6-20. The McGraw-Hill Companies, Inc.
168. E.J. Calabrese, Toxicology rewrites its history and rethinks its future: giving equal focus to both harmful and beneficial effects, Environ. Toxicol. Chem. 30 (2011) 2658-2673.
169. Calabrese E.J., Baldwin L.A. Chemotherapeutics and hormesis. Crit. Rev. Toxicol. 2003, 33:305-354.
170. Calabrese E.J., Baldwin L.A. Inorganics and hormesis. Crit. Rev. Toxicol. 2003, 33:215-304.
171. Calabrese E.J., Baldwin L.A. Peptides and hormesis. Crit. Rev. Toxicol. 2003, 33:355-406.
172. Calabrese E.J., Bachmann K.A., Bailer A.J., Bolger P.M., Borak J., Cai L., Cedergreen N., Cherian M.G., Chiueh C.C., Clarkson T.W., Cook R.R., Diamond D.M., Doolittle D.J., Dorato M.A., Duke S.O., Feinendegen L., Gardner D.E., Hart R.W., Hastings K.L., Hayes A.W., Hoffmann G.R., Ives J.A., Jaworowski Z., Johnson T.E., Jonas W.B., Kaminski N.E., Keller J.G., Klaunig J.E., Knudsen T.B., Kozumbo W.J., Lettieri T., Liu S.Z., Maisseu A., Maynard K.I., Masoro E.J., McClellan R.O., Mehendale H.M., Mothersill C., Newlin D.B., Nigg H.N., Oehme F.W., Phalen R.F., Philbert M.A., Rattan S.I., Riviere J.E., Rodricks J., Sapolsky R.M., Scott B.R., Seymour C., Sinclair D.A., Smith-Sonneborn J., Snow E.T., Spear L., Stevenson D.E., Thomas Y., Tubiana M., Williams G.M., Mattson M.P. Biological stress response terminology: integrating the concepts of adaptive response and preconditioning stress within a hormetic dose-response framework. Toxicol. Appl. Pharmacol. 2007, 222:122-128.
173. Flood J.F., Smith G.E., Cherkin A. Memory retention-enhancement by cholinergic drug combinations in mice. Gerontologist 1982, 22:230-231.
174. Flood J.F., Smith G.E., Cherkin A. Memory retention-potentiation of cholinergic drug-combinations in mice. Neurobiol. Aging 1983, 4:37-43.
175. Flood J.F., Smith G.E., Cherkin A. Memory retention-enhancement by synergistic oral cholinergic drug-combination in mice. Gerontologist 1984, 24:149-158.
176. Flood J.F., Smith G.E., Cherkin A. Memory enhancement-supra-additive effect of subcutaneous chlolinergic drug-combinations in mice. Psychopharmacology 1985, 86:61-67.
177. Calabrese E.J. Neuroscience and hormesis: overview and general findings. Crit. Rev. Toxicol. 2008, 38:249-252.
178. Calabrese E.J., Baldwin L.A. Hormesis and high risk groups. Regul. Toxicol. Pharmacol. 2002, 35:14-428.
179. Calabrese E.J. Cancer biology and hormesis: human tumor cell lines commonly display hormetic (biphasic) dose responses. Crit. Rev. Toxicol. 2005, 35:463-582.
180. Randall W.A., Price C.W., Welch H. Demonstration of hormesis (increase in fatality rate) by penicillin. Am. J. Public Health 1947, 37:421-425.
181. Welch H., Price C.W., Randall W.A. Increase in fatality rate of E. Typhosa for white mice by streptomycin. J. Am. Pharm. 1946, 35:155-158.
182. Abramowitz J., Dai C., Hirschi K.K., Dmitieva R.I., Doris P.A., Liu L., Allen J.C. Ouabain- and marinobufagenin-induced proliferation of human umbilical vein smooth muscle cells and a rat vascular smooth muscle cell lines, A7r5. Circulation 2003, 108:3048-3053.
183. Chueh S.C., Guh J.H., Chen J., Lai M.K., Teng C.M. Dual effects of ouabain on the regulation of proliferation and apoptosis in human prostatic smooth muscle cells. J. Urol. 2001, 166:347-353.
184. Halliwell B. Biochemistry of oxidative stress. Biochem. Soc. Trans. 2007, 35:1147-1150.
185. Calabrese E.J., Stanek E.J., Nascarella M.A., Hoffmann G.R. Hormesis predicts low-dose responses better than threshold models. Int. J. Toxicol. 2008, 27:369-378.
186. Calabrese E.J. Another California milestone: the first application of hormesis in litigation and regulation. Int. J. Toxicol. 2008, 27:31-33.
187. Calabrese E.J. Hormesis and medicine. Br. J. Clin. Pharmacol. 2008, 66:594-617.
188. Calabrese V., Boyd-Kimball D., Scapagnini G., Butterfield D.A. Nitric oxide and cellular stress response in brain aging and neurodegenerative disorders: the role of vitagenes. In Vivo 2004, 18:245-267.
189. Mancuso C., Bates T.E., Butterfield D.A., Calafato S., Cornelius C., De Lorenzo A., Dinkova Kostova A.T., Calabrese V. Mitochondrial dysfunction, free radical generation and cellular stress response in neurodegenerative disorders. Front. Biosci. 2007, 12:1107-1123.
190. Mattson M.P. Hormesis and disease resistance: activation of cellular stress response pathways. Hum. Exp. Toxicol. 2008, 27:155-162.
191. Arumugam T.V., Gleichmann M., Tang S.C., Mattson M.P. Hormesis/preconditioning mechanisms, the nervous system and aging. Ageing Res. Rev. 2006, 5:165-178.
192. Calabrese E.J. Astrocytes: adaptive responses to low doses of neurotoxins. Crit. Rev. Toxicol. 2008, 38:463-471.
193. Calabrese E.J. P-Glycoprotein efflux transporter activity often displays biphasic dose-response relationships. Crit. Rev. Toxicol. 2008, 38:473-487.
194. Zhao J., Kobori N., Aronowski J., Dash P.K. Sulforaphane reduces infarct volume following focal cerebral ischemia in rodents. Neurosci. Lett. 2006, 393:108-112.
195. Zhao J., Moore A.N., Redell J.B., Dash P.K. Enhancing expression of Nrf2-driven genes protects the blood brain barrier after brain injury. J. Neurosci. 2007, 27:10240-10248.
196. Chen C.Y., Jang J.H., Li M.H., Surh Y.J. Resveratrol upregulates heme oxygenase-1 expression via activation of NF-E2-related factor 2 in PC12 cells. Biochem. Biophys. Res. Commun. 2005, 331:993-1000.
197. Hayes J.D., McMahon M. NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem. Sci. 2009, 34:176-188.
198. Kobayashi M., Yamamoto M. Nrf2-Keap1 regulation of cellular defense mechanisms against electrophiles and reactive oxygen species. Adv. Enzyme Regul. 2006, 46:113-140.
199. Motohashi H., Yamamoto M. Nrf2-Keap1 defines a physiologically important stress response mechanism. Trends Mol. Med. 2004, 10:549-557.
200. Dinkova-Kostova A.T. The isothiocyanate sulforaphane inducesthe phase 2 response by signaling of the Keap1-Nrf2-ARE pathway: implications for dietary protection against cancer. Dietary Modulation of Cell Signaling Pathways 2008, 205-229. Y.J. Surh, Z. Dong, E. Cadenas, L. Packer (Eds.).
201. Prochaska H.J., De Long M.J., Talalay P. On the mechanisms of induction of cancer-protective enzymes: a unifying proposal. Proc. Natl. Acad. Sci. U. S. A. 1985, 82:8232-8236.
202. Prochaska H.J., Santamaria A.B., Talalay P. Rapid detection of inducers of enzymes that protect against carcinogens. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:2394-2398.
203. Zhao X., Sun G., Zhang J., Strong R., Dash P.K., Kan Y.W., Grotta J.C., Aronowski J. Transcription factor Nrf2 protects the brain from damage produced by intracerebral hemorrhage. Stroke 2007, 38:3280-3286.
204. Spencer S.R., Wilczak C.A., Talalay P. Induction of glutathione transferases and NAD(P)H:quinone reductase by fumaric acid derivatives in rodent cells and tissues. Cancer Res. 1990, 50:7871-7875.
205. Mancuso C. Heme oxygenase and its products in the nervous system. Antioxid. Redox Signal. 2004, 6:878-887.
206. Calabrese V., Colombrita C., Scapagnini G., Calvani M., Giuffrida Stella A.M., Butterfield D.A. Acetylcarnitine and cellular stress response: role in nutritional redox homeostasis and regulation of longevity genes. J. Nutr. Biochem. 2006, 17:73-88.
207. Stocker R. Antioxidant activities of bile pigments. Antioxid. Redox Signal. 2004, 6:841-849.
208. Mancuso C., Barone E. The heme oxygenase/biliverdin reductase pathway in drug research and development. Curr. Drug Metab. 2009, 10:579-594.
209. Mancuso C., Navarra P., Preziosi P. Roles of nitric oxide, carbon monoxide, and hydrogen sulfide in the regulation of the hypothalamic-pituitary-adrenal axis. J. Neurochem. 2010, 113:563-575.
210. Barone E., Mancuso C., Di Domenico F., Sultana R., Murphy M.P., Head E., Butterfield D.A. Biliverdin reductase-A: a novel drug target for atorvastatin in a dog preclinical model of Alzheimer disease. J. Neurochem. Oct 17, 2011, (Epub ahead of print).
211. Mancuso C., Perluigi M., Cini C., De Marco C., Giuffrida Stella A.M., Calabrese V. Heme oxygenase and cyclooxygenase in the central nervous system: a functional interplay. J. Neurosci. Res. 2006, 84:1385-1391.
212. Mancuso C., Scapagnini G., Curro D., Giuffrida Stella A.M., De Marco C., Butterfield D.A., Calabrese V. Mitochondrial dysfunction, free radical generation and cellular stress response in neurodegenerative disorders. Front. Biosci. 2007, 12:1107-1123.
213. Gerich F.J., Funke F., Hildebrandt B., Faßhauer M., Müller M. H2O2-mediated modulation of cytosolic signaling and organelle function in rat hippocampus. Pflugers Arch. 2009, 458:937-952.
214. Huddleston A.T., Tang W., Takeshima H., Hamilton S.L., Klann E. Superoxide-induced potentiation in the hippocampus requires activation of ryanodine receptor type 3 and ERK. J. Neurophysiol. 2008, 99:1565-1571.
215. Gopalakrishna R., Gundimeda U., Schiffman J.E., McNeill T.H. A direct redox regulation of protein kinase C isoenzymes mediates oxidant-induced neuritogenesis in PC12 cells. J. Biol. Chem. 2008, 283:14430-14444.
216. Terada L.S. Specificity in reactive oxidant signaling: think globally, act locally. J. Cell Biol. 2006, 174:615-623.
217. Mattson M.P., Goodman Y., Luo H., Fu W., Furukawa K. Activation of NF-kappaB protects hippocampal neurons against oxidative stress-induced apoptosis: evidence for induction of manganese superoxide dismutase and suppression of peroxynitrite production and protein tyrosine nitration. J. Neurosci. Res. 1997, 49:681-697.
218. Bruce-Keller A.J., Geddes J.W., Knapp P.E., McFall R.W., Keller J.N., Holtsberg F.W., Parthasarathy S., Steiner S.M., Mattson M.P. Anti-death properties of TNF against metabolic poisoning: mitochondrial stabilization by MnSOD. J. Neuroimmunol. 1999, 93:53-71.
219. Ekdahl C.T., Kokaia Z., Lindvall O. Brain inflammation and adult neurogenesis: the dual role of microglia. Neuroscience 2009, 158:1021-1029.
220. Jiang F., Zhang Z.G., Katakowski M., Robin A.M., Faber M., Zhang F., Chopp M. Angiogenesis induced by photodynamic therapy in normal rat brains. Photochem. Photobiol. 2004, 79:494-498.
221. Halliwell B., Gutteridge J.M.C. Free Radicals in Biology and Medicine 2007, Oxford University Press. fourth ed.
222. Talalay P. Chemoprotection against cancer by induction of phase 2 enzymes. Biofactors 2000, 12:5-11.
223. Gao X., Dinkova-Kostova A.T., Talalay P. Powerful and prolonged protection of human retinal pigment epithelial cells, keratinocytes, and mouse leukemia cells against oxidative damage: the indirect antioxidant effects of sulforaphane. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:15221-15226.
224. Dinkova-Kostova A.T., Holtzclaw W.D., Wakabayashi N. Keap1, the sensor for electrophiles and oxidants that regulates the phase 2 response, is a zinc metalloprotein. Biochemistry 2005, 44:6889-6899.
225. Dinkova-Kostova A.T., Talalay P. Direct and indirect antioxidant properties of inducers of cytoprotective proteins. Mol. Nutr. Food Res. 2008, 52:S128-S138.
226. Rushmore T.H., Pickett C.B. Transcriptional regulation of the rat glutathione S-transferase Ya subunit gene. Characterization of a xenobiotic-responsive element controlling inducible expression by phenolic antioxidants. J. Biol. Chem. 1990, 265:14648-14653.
227. Friling R.S., Bensimon A., Tichauer Y., Daniel V. Xenobiotic-inducible expression of murine glutathione S-transferase Ya subunit gene is controlled by an electrophile-responsive element. Proc. Natl. Acad. Sci. U. S. A. 1990, 87:6258-6262.
228. Rushmore T.H., Morton M.R., Pickett C.B. The antioxidant responsive element. Activation by oxidative stress and identification of the DNA consensus sequence required for functional activity. J. Biol. Chem. 1991, 266:11632-11639.
229. Nioi P., McMahon M., Itoh K., Yamamoto M., Hayes J.D. Identification of a novel Nrf2-regulated antioxidant response element (ARE) in the mouse NAD(P)H:quinone oxidoreductase 1 gene: reassessment of the ARE consensus sequence. Biochem. J. 2003, 374:337-348.
230. Nguyen T., Nioi P., Pickett C.B. The nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J. Biol. Chem. 2009, 284:13291-13295.
231. Hayes J.D., McMahon M., Chowdhry S., Dinkova-Kostova A.T. Cancer chemoprevention mechanisms mediated through the Keap1-Nrf2 pathway. Antioxid. Redox Signal. 2010, 13:1713-1748.
232. Itoh K., Chiba T., Takahashi S., Ishii T., Igarashi K., Katoh Y., Oyake T., Hayashi N., Satoh K., Hatayama I., Yamamoto M., Nabeshima Y. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem. Biophys. Res. Commun. 1997, 236:313-322.
233. Motohashi H., O'Connor T., Katsuoka F., Engel J.D., Yamamoto M. Integration and diversity of the regulatory network composed of Maf and CNC families of transcription factors. Gene 2002, 294:1-12.
234. Itoh K., Wakabayashi N., Katoh Y., Ishii T., Igarashi K., Engel J.D., Yamamoto M. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev. 1999, 13:76-86.
235. Cullinan S.B., Gordan J.D., Jin J., Harper J.W., Diehl J.A. The Keap1-BTB protein is an adaptor that bridges Nrf2 to a Cul3-based E3 ligase: oxidative stress sensing by a Cul3-Keap1 ligase. Mol. Cell. Biol. 2004, 24:8477-8486.
236. Kobayashi A., Kang M.I., Okawa H., Ohtsuji M., Zenke Y., Chiba T., Igarashi K., Yamamoto M. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol. Cell. Biol. 2004, 24:7130-7139.
237. Zhang D.D., Lo S.C., Cross J.V., Templeton D.J., Hannink M. Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. Mol. Cell. Biol. 2004, 24:10941-10953.
238. Furukawa M., Xiong Y. BTB protein Keap1 targets antioxidant transcription factor Nrf2 for ubiquitination by the Cullin 3-Roc1 ligase. Mol. Cell. Biol. 2005, 25:162-171.
239. Talalay P., De Long M.J., Prochaska H.J. Identification of a common chemical signal regulating the induction of enzymes that protect against chemical carcinogenesis. Proc. Natl. Acad. Sci. U. S. A. 1988, 85:8261-8265.
240. Spencer S.R., Xue L.A., Klenz E.M., Talalay P. The potency of inducers of NAD(P)H:(quinone-acceptor) oxidoreductase parallels their efficiency as substrates for glutathione transferases. Structural and electronic correlations. Biochem. J. 1991, 273:711-717.
241. Prestera T., Zhang Y., Spencer S.R., Wilczak C.A., Talalay P. The electrophile counterattack response: protection against neoplasia and toxicity. Adv. Enzyme Regul. 1993, 33:281-296.
242. Dinkova-Kostova A.T., Massiah M.A., Bozak R.E., Hicks R.J., Talalay P. Potency of Michael reaction acceptors as inducers of enzymes that protect against carcinogenesis depends on their reactivity with sulfhydryl groups. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:3404-3409.
243. Dinkova-Kostova A.T., Fahey J.W., Talalay P. Chemical structures of inducers of nicotinamide quinoneoxidoreductase 1 (NQO1). Methods Enzymol. 2004, 382:423-448.
244. Dinkova-Kostova A.T., Holtzclaw W.D., Cole R.N., Itoh K., Wakabayashi N., Katoh Y., Yamamoto M., Talalay P. Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:11908-11913.
245. Kensler T.W., Wakabayashi N., Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu. Rev. Pharmacol. Toxicol. 2007, 47:89-116.
246. Baird L., Dinkova-Kostova A.T. The cytoprotective role of the Keap1-Nrf2 pathway. Arch. Toxicol. 2011, 85:241-272.
247. Dixon R.A. Natural products and plant disease resistance. Nature 2001, 411:843-847.
248. Halkier B.A., Gershenzon J. Biology and biochemistry of glucosinolates. Annu. Rev. Plant Biol. 2006, 7:303-333.
249. Weber H., Chételat A., Reymond P., Farmer E.E. Selective and powerful stress gene expression in Arabidopsis in response to malondialdehyde. Plant J. 2004, 37:877-888.
250. Satoh T., Lipton S.A. Redox regulation of neuronal survival mediated by electrophilic compounds. Trends Neurosci. 2007, 30:37-45.
251. Satoh T., Saitoh S., Hosaka M., Kosaka K. Simple ortho- and para-hydroquinones as compounds neuroprotective against oxidative stress in a manner associated with specific transcriptional activation. Biochem. Biophys. Res. Commun. 2009, 379:537-541.
252. Bensasson R.V., Zoete V., Dinkova-Kostova A.T., Talalay P. Two-step mechanism of induction of the gene expression of a prototypic cancer-protective enzyme by diphenols. Chem. Res. Toxicol. 2008, 21:805-812.
253. Wang X.J., Hayes J.D., Higgins L.G., Wolf C.R., Dinkova-Kostova A.T. Activation of the NRF2 signaling pathway by copper-mediated redox cycling of para- and ortho-hydroquinones. Chem. Biol. 2010, 17:75-85.
254. Dinkova-Kostova A.T., Wang X.J. Induction of the Keap1/Nrf2/ARE pathway by oxidizable diphenols. Chem. Biol. Interact. 2011, 192:101-106.
255. Lipton S.A. Pathologically activated therapeutics for neuroprotection. Nat. Rev. Neurosci. 2007, 8:803-808.
256. Kosaka K., Yokoi T. Carnosic acid, a component of rosemary (Rosmarinus officinalis L.), promotes synthesis of nerve growth factor in T98G human glioblastoma cells. Biol. Pharm. Bull. 2003, 26:1620-1622.
257. Doolaege E.H., Raes K., De Vos F., Verhé R., De Smet S. Absorption, distribution and elimination of carnosic acid, a natural antioxidant from Rosmarinus officinalis, in rats. Plant Foods Hum. Nutr. 2011, 66:196-202.
258. Satoh T., Kosaka K., Itoh K., Kobayashi A., Yamamoto M., Shimojo Y., Kitajima C., Cui J., Kamins J., Okamoto S., Izumi M., Shirasawa T., Lipton S.A. Carnosic acid, a catechol-type electrophilic compound, protects neurons both in vitro and in vivo through activation of the Keap1/Nrf2 pathway via S-alkylation of targeted cysteines on Keap1. J. Neurochem. 2008, 104:1116-1131.
259. Tamaki Y., Tabuchi T., Takahashi T., Kosaka K., Satoh T. Activated glutathione metabolism participates in protective effects of carnosic acid against oxidative stress in neuronal HT22 cells. Planta Med. 2010, 76:683-688.
260. Kosaka K., Mimura J., Itoh K., Satoh T., Shimojo Y., Kitajima C., Maruyama A., Yamamoto M., Shirasawa T. Role of Nrf2 and p62/ZIP in the neurite outgrowth by carnosic acid in PC12h cells. J. Biochem. 2010, 147:73-81.
261. Mimura J., Kosaka K., Maruyama A., Satoh T., Harada N., Yoshida H., Satoh K., Yamamoto M., Itoh K. Nrf2 regulates NGF mRNA induction by carnosic acid in T98G glioblastoma cells and normal human astrocytes. J. Biochem. 2011, 150:209-217.
262. Vaka S.R., Murthy S.N., Repka M.A., Nagy T. Upregulation of endogenous neurotrophin levels in the brain by intranasal administration of carnosic acid. J. Pharm. Sci. 2011, 100:3139-3145.
263. Luft R., Ikkos D., Palmieri G., Ernster L., Afzelius A. A case of severe hypermetabolism of nonthyroid origin with a defect in the maintenance of mitochondrial respiratory control: a correlated clinical, biochemical and morphological study. J. Clin. Invest. 1962, 41:1776-1804.
264. Zhang Y., Talalay P., Cho C.G., Posner G.H. A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of structure. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:2399-2403.
265. Kraft A.D., Johnson D.A., Johnson J.A. Nuclear factor E2-related factor 2-dependent antioxidant response element activation by tert-butylhydroquinone and sulforaphane occurring preferentially in astrocytes conditions neurons against oxidative insult. J. Neurosci. 2004, 24:1101-1112.
266. Danilov C.A., Chandrasekaran K., Racz J., Soane L., Zielke C., Fiskum G. Sulforaphane protects astrocytes against oxidative stress and delayed death caused by oxygen and glucose deprivation. Glia 2009, 57:645-656.
267. Bergström P., Andersson H.C., Gao Y., Karlsson J.O., Nodin C., Anderson M.F., Nilsson M., Hammarsten O. Repeated transient sulforaphane stimulation in astrocytes leads to prolonged Nrf2-mediated gene expression and protection from superoxide-induced damage. Neuropharmacology 2011, 60:343-353.
268. Vincent A.M., Kato K., McLean L.L., Soules M.E., Feldman E.L. Sensory neurons and schwann cells respond to oxidative stress by increasing antioxidant defense mechanisms. Antioxid. Redox Signal. 2009, 11:425-438.
269. Siebert A., Desai V., Chandrasekaran K., Fiskum G., Jafri M.S. Nrf2 activators provide neuroprotection against 6-hydroxydopamine toxicity in rat organotypic nigrostriatal cocultures. J. Neurosci. Res. 2009, 87:1659-1669.
270. Vauzour D., Buonfiglio M., Corona G., Chirafisi J., Vafeiadou K., Angeloni C., Hrelia S., Hrelia P., Spencer S.P. Sulforaphane protects cortical neurons against 5-S-cysteinyl-dopamine-induced toxicity through the activation of ERK1/2, Nrf-2 and the upregulation of detoxification enzymes. Mol. Nutr. Food Res. 2010, 54:532-542.
271. Soane L., Li Dai W., Fiskum G., Bambrick L.L. Sulforaphane protects immature hippocampal neurons against death caused by exposure to hemin or to oxygen and glucose deprivation. J. Neurosci. Res. 2010, 88:1355-1363.
272. Chang G., Guo Y., Jia Y., Duan W., Li B., Yu J., Li C. Protective effect of combination of sulforaphane and riluzole on glutamate-mediated excitotoxicity. Biol. Pharm. Bull. 2010, 33:1477-1483.
273. Rojo A.I., Rada P., Egea J., Rosa A.O., López M.G., Cuadrado A. Functional interference between glycogen synthase kinase-3 beta and the transcription factor Nrf2 in protection against kainate-induced hippocampal cell death. Mol. Cell. Neurosci. 2008, 39:125-132.
274. Greco T., Fiskum G. Brain mitochondria from rats treated with sulforaphane are resistant to redox-regulated permeability transition. J. Bioenerg. Biomembr. 2010, 42:491-497.
275. Zhao J., Moore A.N., Clifton G.L., Dash P.K. Sulforaphane enhances aquaporin-4 expression and decreases cerebral edema following traumatic brain injury. J. Neurosci. Res. 2005, 82:499-506.
276. Zhao X., Song S., Sun G., Strong R., Zhang J., Grotta J.C., Aronowski J. Neuroprotective role of haptoglobin after intracerebral hemorrhage. J. Neurosci. 2009, 29:15819-15827.
277. Chen G., Fang Q., Zhang J., Zhou D., Wang Z. Role of the Nrf2-ARE pathway in early brain injury after experimental subarachnoid hemorrhage. J. Neurosci. Res. 2011, 89:515-523.
278. Hong Y., Yan W., Chen S., Sun C.R., Zhang J.M. The role of Nrf2 signaling in the regulation of antioxidants and detoxifying enzymes after traumatic brain injury in rats and mice. Acta Pharmacol. Sin. 2010, 31:1421-1430.
279. Dash P.K., Zhao J., Orsi S.A., Zhang M., Moore A.N. Sulforaphane improves cognitive function administered following traumatic brain injury. Neurosci. Lett. 2009, 460:103-107.
280. Ping Z., Liu W., Kang Z., Cai J., Wang Q., Cheng N., Wang S., Wang S., Zhang J.H., Sun X. Sulforaphane protects brains against hypoxic-ischemic injury through induction of Nrf2-dependent phase 2 enzyme. Brain Res. 2010, 1343:178-185.
281. Wierinckx A., Brevé J., Mercier D., Schultzberg M., Drukarch B., Van Dam A.M. Detoxication enzyme inducers modify cytokine production in rat mixed glial cells. J. Neuroimmunol. 2005, 166:132-143.
282. Innamorato N.G., Rojo A.I., Garcìa-Yagüe A.J., Yamamoto M., de Ceballos M.L., Cuadrado A. The transcription factor Nrf2 is a therapeutic target against brain inflammation. J. Immunol. 2008, 181:680-689.
283. Rojo A.I., Innamorato N.G., Martín-Moreno A.M., De Ceballos M.L., Yamamoto M., Cuadrado A. Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease. Glia 2010, 58:588-598.
284. Innamorato N.G., Jazwa A., Rojo A.I., García C., Fernández-Ruiz J., Grochot-Przeczek A., Stachurska A., Jozkowicz A., Dulak J., Cuadrado A. Different susceptibility to the Parkinson's toxin MPTP in mice lacking the redox master regulator Nrf2 or its target gene heme oxygenase-1. PLoS One 2010, 5:11838.
285. Jazwa A., Rojo A.I., Innamorato N.G., Hesse M., Fernández-Ruiz J., Cuadrado A. Pharmacological targeting of the transcription factor nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism. Antioxid. Redox Signal. 2011, 14:2347-2360.
286. Kim D., You B., Jo E.K., Han S.K., Simon M.I., Lee S.J. NADPH oxidase 2-derived reactive oxygen species in spinal cord microglia contribute to peripheral nerve injury-induced neuropathic pain. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:14851-14856.
287. Mao L., Wang H., Wang X., Liao H., Zhao X. Transcription factor nrf2 protects the spinal cord from inflammation produced by spinal cord injury. J. Surg. Res. 2011, 170:105-115.
288. X. Wang, J.P. De Rivero Vaccari, H. Wang, P. Diaz, R. German, A. Marcillo, R.W. Keane, Activation of the nuclear factor E2-related factor 2/antioxidant response element pathway is neuroprotective following spinal cord injury, J. Neurotrauma (Sep 21, 2011, Electronic publication ahead of print).
289. Toyama T., Shinkai Y., Yasutake A., Uchida K., Yamamoto M., Kumagai Y. Isothiocyanates reduce mercury accumulation via an Nrf2-dependent mechanism during exposure of mice to methylmercury. Environ. Health Perspect. 2011, 119:1117-1122.
290. Begleiter A., Sivananthan K., Curphey T.J., Bird R.P. Induction of NAD(P)H quinone: oxidoreductase1 inhibits carcinogen-induced aberrant crypt foci in colons of Sprague-Dawley rats. Cancer Epidemiol. Biomarkers Prev. 2003, 12:566-572.
291. Schilling S., Goelz S., Linker R., Luehder F., Gold R. Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clin. Exp. Immunol. 2006, 145:101-107.
292. Ellrichmann G., Petrasch-Parwez E., Lee D.H., Reick C., Arning L., Saft C., Gold R., Linker R.A. Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease. PLoS One 2011, 6:16172.
293. Linker R.A., Lee D.H., Ryan S., van Dam A.M., Conrad R., Bista P., Zeng W., Hronowsky X., Buko A., Chollate S., Ellrichmann G., Brück W., Dawson K., Goelz S., Wiese S., Scannevin R.H., Lukashev M., Gold R. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 2011, 134:678-692.
294. Nieboer C., de Hoop D., Langendijk P.N., van Loenen A.C., Gubbels J. Fumaric acid therapy in psoriasis: a double-blind comparison between fumaric acid compound therapy and monotherapy with dimethylfumaric acid ester. Dermatologica 1990, 181:33-37.
295. Altmeyer P.J., Matthes U., Pawlak F., Hoffmann K., Frosch P.J., Ruppert P., Wassilew S.W., Horn T., Kreysel H.W., Lutz G. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients. J. Am. Acad. Dermatol. 1994, 30:977-981.
296. Zlotkin S. A new approach to control of anemia in "at risk" infants and children around the world, Ryley-Jeffs memorial lecture. Can. J. Diet. Pract. Res. 2004, 65:136-138.
297. Schimrigk S., Brune N., Hellwig K., Lukas C., Bellenberg B., Rieks M., Hoffmann V., Pöhlau D., Przuntek H. Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. Eur. J. Neurol. 2006, 13:604-610.
298. Kappos L., Gold R., Miller D.H., Macmanus D.G., Havrdova E., Limmroth V., Polman C.H., Schmierer K., Yousry T.A., Yang M., Eraksoy M., Meluzinova E., Rektor I., Dawson K.T., Sandrock A.W., O'Neill G.N. BG-12 phase IIb study investigators. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008, 372:1463-1472.
299. Trial watch: phase III success for Biogen's oral multiple sclerosis therapy. Nat. Rev. Drug Discov. 2011, 10:404.
300. Jang M., Cai L., Udeani G.O., Slowing K.V., Thomas C.F., Beecher C.W., Fong H.H., Farnsworth N.R., Kinghorn A.D., Mehta R.G., Moon R.C., Pezzuto J.M. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997, 275:218-220.
301. Soleas G.J., Diamandis E.P., Goldberg D.M. Resveratrol: a molecule whose time has come? And gone?. Clin. Biochem. 1997, 30:91-113.
302. Pezzuto J.M. The phenomenon of resveratrol: redefining the virtues of promiscuity. Ann. N. Y. Acad. Sci. 2011, 1215:123-130.
303. Jang J.H., Surh Y.J. Protective effects of resveratrol on hydrogen peroxide-induced apoptosis in rat pheochromocytoma (PC12) cells. Mutat. Res. 2001, 496:181-190.
304. Conte A., Pellegrini S., Tagliazucchi D. Effect of resveratrol and catechin on PC12 tyrosine kinase activities and their synergistic protection from beta-amyloid toxicity. Drugs Exp. Clin. Res. 2003, 29:243-255.
305. Sun A.Y., Chen Y.M., James-Kracke M., Wixom P., Cheng Y. Ethanol-induced cell death by lipid peroxidation in PC12 cells. Neurochem. Res. 1997, 22:1187-1192.
306. Draczynska-Lusiak B., Chen Y.M., Sun A.Y. Oxidized lipoproteins activate NF-kappaB binding activity and apoptosis in PC12 cells. Neuroreport 1998, 9:527-532.
307. Draczynska-Lusiak B., Doung A., Sun A.Y. Oxidized lipoproteins may play a role in neuronal cell death in Alzheimer disease. Mol. Chem. Neuropathol. 1998, 33:139-148.
308. Siddiqui M.A., Kashyap M.P., Kumar V., Al-Khedhairy A.A., Musarrat J., Pant A.B. Protective potential of trans-resveratrol against 4-hydroxynonenal induced damage in PC12 cells. Toxicol. In Vitro 2010, 24:1592-1598.
309. Agrawal M., Kumar V., Kashyap M.P., Khanna V.K., Randhawa G.S., Pant A.B. Ischemic insult induced apoptotic changes in PC12 cells: protection by trans resveratrol. Eur. J. Pharmacol. 2011, 666:5-11.
310. Chanvitayapongs S., Draczynska-Lusiak B., Sun A.Y. Amelioration of oxidative stress by antioxidants and resveratrol in PC12 cells. Neuroreport 1997, 8:1499-1502.
311. Y. Wu, X. Li, J.X. Zhu, W. Xie, W. Le, Z. Fan, J. Jankovic, T. Pan, Resveratrol-activated AMPK/SIRT1/autophagy in cellular models of Parkinson's disease, Neurosignals 19 (2011) 163-174.
312. Rivière C., Richard T., Quentin L., Krisa S., Mérillon J.M., Monti J.P. Inhibitory activity of stilbenes on Alzheimer's beta-amyloid fibrils in vitro. Bioorg. Med. Chem. 2007, 15:1160-1167.
313. dos Santos A.Q., Nardin P., Funchal C., de Almeida L.M., Jacques-Silva M.C., Wofchuk S.T., Gonçalves C.A., Gottfried C. Resveratrol increases glutamate uptake and glutamine synthetase activity in C6 glioma cells. Arch. Biochem. Biophys. 2006, 453:161-167.
314. de Almeida L.M., Piñeiro C.C., Leite M.C., Brolese G., Tramontina F., Feoli A.M., Gottfried C., Gonçalves C.A. Resveratrol increases glutamate uptake, glutathione content, and S100B secretion in cortical astrocyte cultures. Cell. Mol. Neurobiol. 2007, 27:661-668.
315. de Almeida L.M., Leite M.C., Thomazi A.P., Battu C., Nardin P., Tortorelli L.S., Zanotto C., Posser T., Wofchuk S.T., Leal R.B., Gonçalves C.A., Gottfried C. Resveratrol protects against oxidative injury induced by H2O2 in acute hippocampal slice preparations from Wistar rats. Arch. Biochem. Biophys. 2008, 480:27-32.
316. Maher P., Dargusch R., Bodai L., Gerard P.E., Purcell J.M., Marsh J.L. ERK activation by the polyphenols fisetin and resveratrol provides neuroprotection in multiple models of Huntington's disease. Hum. Mol. Genet. 2011, 20:261-270.
317. Pallos J., Bodai L., Lukacsovich T., Purcell J.M., Steffan J.S., Thompson L.M., Marsh J.L. Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease. Hum. Mol. Genet. 2008, 17:3767-3775.
318. Albani D., Polito L., Signorini A., Forloni G. Neuroprotective properties of resveratrol in different neurodegenerative disorders. Biofactors 2010, 36:370-376.
319. Liu C., Shi Z., Fan L., Zhang C., Wang K., Wang B. Resveratrol improves neuron protection and functional recovery in rat model of spinal cord injury. Brain Res. 2011, 1374:100-109.
320. Yang Y.B., Piao Y.J. Effects of resveratrol on secondary damages after acute spinal cord injury in rats. Acta Pharmacol. Sin. 2003, 24:703-710.
321. Kiziltepe U., Turan N.N., Han U., Ulus A.T., Akar F. Resveratrol, a red wine polyphenol, protects spinal cord from ischemia-reperfusion injury. J. Vasc. Surg. 2004, 40:138-145.
322. Kaplan S., Bisleri G., Morgan J.A., Cheema F.H., Oz M.C. Resveratrol, a natural red wine polyphenol, reduces ischemia-reperfusion-induced spinal cord injury. Ann. Thorac. Surg. 2005, 80:2242-2249.
323. Ates O., Cayli S., Altinoz E., Gurses I., Yucel N., Kocak A., Yologlu S., Turkoz Y. Effects of resveratrol and methylprednisolone on biochemical, neurobehavioral and histopathological recovery after experimental spinal cord injury. Acta Pharmacol. Sin. 2006, 27:1317-1325.
324. Huang S.S., Tsai M.C., Chih C.L., Hung L.M., Tsai S.K. Resveratrol reduction of infarct size in Long-Evans rats subjected to focal cerebral ischemia. Life Sci. 2001, 69:1057-1065.
325. Tsai S.K., Hung L.M., Fu Y.T., Cheng H., Nien M.W., Liu H.Y., Zhang F.B., Huang S.S. Resveratrol neuroprotective effects during focal cerebral ischemia injury via nitric oxide mechanism in rats. J. Vasc. Surg. 2007, 46:346-353.
326. J. Ren, C. Fan, N. Chen, J. Huang, Q. Yang, Resveratrol pretreatment attenuates cerebral ischemic injury by upregulating expression of transcription factor Nrf2 and HO-1 in rats, Neurochem. Res. 36 (2011) 2352-2362.
327. Kumar A., Singh C.K., Lavoie H., Dipette D., Singh U. Resveratrol restores Nrf2 level and prevents ethanol-induced toxic effects in the cerebellum of a rodent model of Fetal Alcohol Spectrum Disorders. Mol. Pharmacol. 2011, 80:446-457.
328. Nakagawa H., Kiyozuka Y., Uemura Y., Senzaki H., Shikata N., Hioki K., Tsubura A. Resveratrol inhibits human breast cancer cell growth and may mitigate the effect of linoleic acid, a potent breast cancer cell stimulator. J. Cancer Res. Clin. Oncol. 2001, 127:258-264.
329. Basly J.P., Marre-Fournier F., Le Bail J.C., Habrioux G., Chulia A.J. Estrogenic/antiestrogenic and scavenging properties of (E)- and (Z)-resveratrol. Life Sci. 1999, 66:769-777.
330. Schmitt E., Lehmann L., Metzler M., Stopper H. Hormonal and genotoxic activity of resveratrol. Toxicol. Lett. 2002, 136:133-142.
331. Liu R., Serrero G. Resveratrol, a natural product derived from grape, exhibits antiestrogenic activity and inhibits the growth of human breast cancer cells. J. Cell. Physiol. 1999, 179:297-304.
332. Gehm B.D., Mcandrews J.M., Chien P.Y., Jameson J.L. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:14138-14143.
333. Pozo-Guisado E., Lorenzo-Benayas M.J., Fernandez-Salguero P.M. Resveratrol modulates the phosphoinositide 3-kinase pathway through an estrogen receptor a-dependent mechanism: relevance in cell proliferation. Int. J. Cancer 2004, 109:167-173.
334. Li Y., Liu J., Liu X., Xing K., Wang Y., Li F., Yao L. Resveratrol-induced cell inhibition of growth and apoptosis in MCF7 human breast cancer cells are associated with modulation of phosphorylated Akt and caspase-9. Appl. Biochem. Biotechnol. 2006, 135:181-192.
335. Vyas S., Asmerom Y., De Leon D.D. Resveratrol regulates insulin-like growth factor-II in breast cancer cells. Endocrinology 2005, 146:4224-4233.
336. Hsieh T.C., Wu J.M. Differential effects on growth, cell cycle arrest, and induction of apoptosis by resveratrol in human prostate cancer cell lines. Exp. Cell Res. 1999, 249:109-115.
337. Kuwajerwala N., Cifuentes E., Gautam S., Menon M., Barrack E.R., Veer Reddy G.P. Resveratrol induces prostate cancer cell entry into S phase and inhibits DNA synthesis. Cancer Res. 2002, 62:2488-2492.
338. Benitez D.A., Pozo-Guisado E., Alvarez-Barrientos A., Fernandez-Salguero P.M., Castellón E.A. Mechanisms involved in resveratrol-induced apoptosis and cell cycle arrest in prostate cancer-derived cell lines. J. Androl. 2007, 28:282-293.
339. Wang T.T., Hudson T.S., Wang T.C., Remsberg C.M., Davies N.M., Takahashi Y., Kim Y.S., Seifried H., Vinyard B.T., Perkins S.N., Hursting S.D. Differential effects of resveratrol on androgen-responsive LNCaP human prostate cancer cells in vitro and in vivo. Carcinogenesis 2008, 29:2001-2010.
340. Lee S.K., Zhang W., Sanderson B.J.S. Selective growth inhibition of human leukemia and human lymphoblastoid cells by resveratrol via cell cycle arrest and apoptosis induction. J. Agric. Food Chem. 2008, 56:7572-7577.
341. Bernhard D., Schwaiger W., Crazzolara R., Tinhofer I., Kofler R., Csordas A. Enhanced MTT-reducing activity under growth inhibition by resveratrol in CEM-C7H2 lymphocytic leukemia cells. Cancer Lett. 2003, 195:193-199.
342. Szende B., Tyihak E., Kiraly-Veghely Z. Dose-dependent effect of resveratrol on proliferation and apoptosis in endothelial and tumor cell cultures. Exp. Mol. Med. 2000, 32:88-92.
343. Hope C., Planutis K., Planutiene M., Moyer M.P., Johal K.S., Woo J., Santoso C., Hanson J.A., Holcombe R.F. Low concentrations of resveratrol inhibit Wnt signal throughput in colon-derived cells: implications for colon cancer prevention. Mol. Nutr. Food Res. 2008, 52:S52-S61.
344. Sexton E., Van Themsche C., Leblanc K., Parent S., Lemoine P., Asselin E. Resveratrol interferes with AKT activity and triggers apoptosis in human uterine cancer cells. Mol. Cancer 2006, 5:45-58.
345. Kimura Y., Okuda H. Resveratrol isolated from Polygonum cuspidatum root prevents tumor growth and metastasis to lung and tumor-induced neovascularization in Lewis lung carcinoma-bearing mice. J. Nutr. 2001, 131:1844-1849.
346. Gu J., Wang C.Q., Fan H.H., Ding H.Y., Xie X.L., Xu Y.M., Wang B.Y., Huang D.J. Effects of resveratrol on endothelial progenitor cells and their contributions to reendothelialization in intima-injured rats. J. Cardiovasc. Pharmacol. 2006, 47:711-721.
347. Xia L., Wang X.X., Hu X.S., Guo x.g., Shang Y.P., Chen H.J., Zeng C.L., Zhang F.R., Chen J.Z. Resveratrol reduces endothelial progenitor cells senescence through augmentation of telomerase activity by Akt-dependent mechanisms. Br. J. Pharmacol. 2008, 155:387-394.
348. In K., Park J., Park H. Resveratrol at high doses acts as an apoptotic inducer in endothelial cells. Cancer Res. Treat. 2006, 38:48-53.
349. Subbaranmaiah K., Chung W.J., Michaluart P., Telang N., Tanabe T., Inoue H., Jang M., Pezzuto J.M., Dannenberg A.J. Resveratrol inhibits cyclo-oxigenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J. Biol. Chem. 1998, 273:21875-21882.
350. Martinez J., Moreno J.J. Effect of resveratrol, a natural polyphenolic compound, on reactive oxygen species and prostaglandin production. Biochem. Pharmacol. 2000, 59:865-870.
351. Falchetti R., Fuggetta M.P., Lanzilli G., Tricarico M., Ravagnan G. Effects of resveratrol on human immune cell function. Life Sci. 2001, 70:81-96.
352. Gao X., Xu Y.X., Janakiraman N., Chapman R.A., Gautam S.C. Immunomodulatory activity of resveratrol: suppression of lymphocyte proliferation, development of cell-mediated cytotoxicity, and cytokine production. Biochem. Pharmacol. 2001, 62:1299-1308.
353. Gao X., Deeb D., Media J., Divine G., Jiang H., Chapman R.A., Gautam S.C. Immunomodulatory activity of resveratrol: discrepant in vitro and in vivo immunological effects. Biochem. Pharmacol. 2003, 66:2427-2435.
354. Juan S.H., Cheng T.H., Lin H.C., Chu Y.L., Lee W.S. Mechanism of concentration-dependent induction of heme oxygenase-1 by resveratrol in human aortic smooth muscle cells. Biochem. Pharmacol. 2005, 69:41-48.
355. Dudley J., Das S., Mukherjee S., Das D.K. Resveratrol, a unique phytoalexin present in red wine, delivers either survival signal or death signal to the ischemic myocardium depending on dose. J. Nutr. Biochem. 2009, 20:443-452.
356. Dai Z., Li Y., Quarles L.D., Song T., Pan W., Zhou H., Xiao Z. Resveratrol enhances proliferation and osteoblastic differentiation in human mesenchymal stem cells via ER-dependent ERK1/2 activation. Phytomedicine 2007, 14:806-814.
357. Dey A., Guha P., Chattopadhyay S., Bandyopadhyay S.K. Biphasic activity of resveratrol on indomethacin-induced gastric ulcers. Biochem. Biophys. Res. Commun. 2009, 381:90-95.
358. Alarcón de la Lastra C. Commentary on 'resveratrol commonly displays hormesis: occurrence and biomedical significance' by Calabrese et al. Hum. Exp. Toxicol. 2010, 29:1021-1023.
359. Kedzierski L., Curtis J.M., Kaminska M., Jodynis-Liebert J., Murias M. In vitro antileishmanial activity of resveratrol and its hydroxylated analogues against Leishmania major promastigotes and amastigotes. Parasitol. Res. 2007, 102:91-97.
360. Ozkoc S., Tuncay S., Delibas S.B., Akisu C. In vitro effects of resveratrol on Trichinella spiralis. Parasitol. Res. 2009, 105:1139-1143.
361. Lindsay D.G. Commentary on 'resveratrol commonly displays hormesis: occurrence and biomedical significance'. Hum. Exp. Toxicol. 2010, 29:1024-1025.
362. Hagen T.M., Liu J.K., Lykkesfeldt J., Wehr C.M., Ingersoll R.T., Vinarsky V., Bartholomew J.C., Ames B.N. Feeding acetyl-L-carnitine and lipoic acid to old rats significantly improves metabolic function while decreasing oxidative stress. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:1870-1875.
363. Hagen T.M., Moreau R., Suh J.H., Visioli F. Mitochondrial decay in the aging rat heart: evidence for improvement by dietary supplementation with acetyl-L-carnitine and/or lipoic acid. Ann. N. Y. Acad. Sci. 2002, 959:491-507.
364. Calabrese V., Colombrita C., Sultana R., Scapagnini G., Calvani M., Butterfield D.A., Giuffrida Stella A.M. Redox modulation of heat shock protein expression by acetylcarnitine in aging brain: relationship to antioxidant status and mitochondrial function. Antioxid. Redox Signal. 2006, 8:404-416.
365. Krajcovicova-Kudlackova M., Simonic R., Bederova A., Babinska K., Béder I. Correlation of carnitine levels to methionine and lysine intake. Physiol. Res. 2000, 49:399-402.
366. Hoppel C. The role of carnitine in normal and alterated fatty acid metabolism. Am. J. Kidney Dis. 2003, 41:S4-S12.
367. Steiber A., Kerner J., Hoppel C.L. Carnitine: a nutritional, biosynthetic and functional perspective. Mol. Aspects Med. 2004, 25:455-473.
368. Schinetti M.L., Rossini D., Greco R., Bertelli A. Protective action of acetylcarnitine on NADPH induced lipid peroxidation of cardiac microsomes. Drugs Exp. Clin. Res. 1987, 13:509-515.
369. Liu J., Head E., Kuratsune H., Cotman C.W., Ames B.N. Comparison of the effects of L-carnitine and acetyl-L-carnitine on carnitine levels, ambulatory activity, and oxidative stress biomarkers in the brain of old rats. Ann. N. Y. Acad. Sci. 2004, 1033:117-131.
370. Poon H.F., Calabrese V., Calvani M., Butterfield D.A. Proteomics analyses of specific protein oxidation and protein expression in aged rat brain and its modulation by L-acetylcarnitine: insights into the mechanisms of action of this proposed therapeutic agent for CNS disorders associated with oxidative stress. Antioxid. Redox Signal. 2006, 8:381-394.
371. Calabrese V., Giuffrida Stella A.M., Calvani M., Butterfield D.A. Acetylcarnitine and cellular stress response: roles in nutritional redox homeostasis and regulation of longevity genes. J. Nutr. Biochem. 2006, 17:73-88.
372. Abdul H.M., Calabrese V., Calvani M., Butterfield D.A. Acetyl-L-carnitine-induced up-regulation of heat shock proteins protects cortical neurons against amyloid-beta peptide 1-42-mediated oxidative stress and neurotoxicity: implications for Alzheimer's disease. J. Neurosci. Res. 2006, 84:398-408.
373. Abdul H.M., Butterfield D.A. Involvement of PI3K/PKG/ERK1/2 signaling pathways in cortical neurons to trigger protection by cotreatment of acetyl-L-carnitine and alpha-lipoic acid against HNE-mediated oxidative stress and neurotoxicity: implications for Alzheimer's disease. Free Radic. Biol. Med. 2007, 42:371-384.
374. Virmani M.A., Biselli R., Spadoni A., Rossi S., Corsico N., Calvani M., Fattorossi A., De Simone C., Arrigoni-Martelli E. Protective actions of L-carnitine and acetyl-L-carnitine on the neurotoxicity evoked by mitochondrial uncoupling or inhibitors. Pharmacol. Res. 1995, 32:383-389.
375. Virmani M.A., Caso V., Spadoni A., Rossi S., Russo F., Gaetani F. The action of acetyl-L-carnitine on the neurotoxicity evoked by amyloid fragments and peroxide on primary rat cortical neurons. Neuroprotect. Agents 2001, 939:162-178.
376. Lowitt S., MaloneI J.I., Salem A.F., Korthals J., Benford S. Acetyl-L-carnitine corrects the altered peripheral nerve function of experimental diabetes. Metabolism 1995, 44:677-680.
377. Reznick A.Z., Kagan V.E., Ramsey R., Tsuchiya M., Khwaja S., Serbinova E.A., Packer L. Antiradical effects in L-propionyl carnitine protection of the heart against ischemia-reperfusion injury: the possible role of iron chelation. Arch. Biochem. Biophys. 1992, 296:394-401.
378. Calabrese V., Ravagna A., Colombrita C., Scapagnini G., Guagliano E., Calvani M., Butterfield D.A., Giuffrida Stella A.M. Acetylcarnitine induces heme oxygenase in rat astrocytes and protects against oxidative stress: involvement of the transcription factor Nrf2. J. Neurosci. Res. 2005, 79:509-521.
379. Liu J., Ames B.N. Reducing mitochondrial decay with mitochondrial nutrients to delay and treat cognitive dysfunction, Alzheimer's disease, and Parkinson's disease. Nutr. Neurosci. 2005, 8:67-89.
380. Shen W., Liu K., Tian C., Yang L., Li X., Ren J., Packer L., Head E., Sharman E., Liu J. Protective effects of R-alpha-lipoic acid and acetyl-L-carnitine in MIN6 and isolated rat islet cells chronically exposed to oleic acid. J. Cell. Biochem. 2008, 104:1232-1243.
381. Lesnefsky E.J., He D., Moghaddas S., Hoppel C.L. Reversal of mitochondrial defects before ischemia protects the aged heart. FASEB J. 2006, 20:1543-1545.
382. McDaniel M.A., Maier S.F., Einstein G.O. "Brain-specific" nutrients: a memory cure?. Nutrition 2003, 19:957-975.
383. Calabrese V., Calvani M., Butterfield D.A. Increased formation of short-chain organic acids after chronic ethanol administration and its interaction with the carnitine pool in rat. Arch. Biochem. Biophys. 2004, 431:271-278.
384. Calabrese V., Butterfield D.A., Scapagnini G., Stella A.M., Maines M.D. Redox regulation of heat shock protein expression by signaling involving nitric oxide and carbon monoxide: relevance to brain aging, neurodegenerative disorders, and longevity. Antioxid. Redox Signal. 2006, 8:444-477.
385. Calabrese V., Calvani M., Butterfield D.A. Acetyl-L-carnitine-induced up-regulation of heat shock proteins protects cortical neurons against amyloid-beta peptide 1-42-mediated oxidative stress and neurotoxicity: implications for Alzheimer's disease. J. Neurosci. Res. 2006, 84:398-408.
386. Calabrese V., Pennisi G., Calvani M., Giuffrida Stella A.M., Butterfield D.A., Mancuso C. Heme oxygenase as therapeutic funnel in nutritional redox homeostasis and cellular stress response: role of acetylcarnitine. Heat Shock Protein in Neural Cells 2006, 39-52. USA, Springer, N.Y. C. Ritcher-Landsberg (Ed.).
387. Calabrese V., Colombrita C., Guagliano E., Sapienza M., Ravagna A., Cardile V., Scapagnini G., Santoro A.M., Mangiameli A., Butterfield D.A., Giuffrida Stella A.M., Rizzarelli E. Protective effect of carnosine during nitrosative stress in astroglial cell cultures. Neurochem. Res. 2005, 30:797-807.
388. Furuno T., Kanno T., Arita K., Asami M., Utsumi T., Doi Y., Inoue M., Utsumi K. Roles of long chain fatty acids and carnitine in mitochondrial membrane permeability transition. Biochem. Pharmacol. 2001, 62:1037-1046.
389. Pillich R.T., Scarsella G., Risuleo G. Reduction of apoptosis through the mitochondrial pathway by the administration of acetyl-L-carnitine to mouse fibroblasts in culture. Exp. Cell Res. 2005, 306:1-8.
390. Ishii T., Shimpo Y., Matsuoka Y., Kinoshita K. Anti-apoptotic effect of acetyl-L-carnitine and L-carnitine in primary cultured neurons. Jpn. J. Pharmacol. 2000, 83:119-124.
391. Arrigoni-Martelli E., Caso V. Carnitine protects mitochondria and removes toxic acyls from xenobiotics. Drugs Exp. Clin. Res. 2001, 27:27-49.
392. Galli G., Fratelli M. Activation of apoptosis by serum deprivation in a teratocarcinoma cell line: inhibition by L-acetylcarnitine. Exp. Cell Res. 1993, 204:54-60.
393. Revoltella R.P., Dal Canto B., Caracciolo L., D'urso C.M. L-Carnitine and some of its analogs delay the onset of apoptotic cell death initiated in murine C2.8 hepatocytic cells after hepatocyte growth factor deprivation. Biochim. Biophys. Acta 1994, 1224:333-341.
394. Snyder J.W., Kyle M.E., Ferraro T.N. L-carnitine delays the killing of cultured hepatocytes by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Arch. Biochem. Biophys. 1990, 276:132-138.
395. Moretti S., Famularo G., Marcellini S. L-Carnitine reduces lymphocyte apoptosis and oxidant stress in HIV-1 infected subjects treated with zidovudine and didanosine. Antioxid. Redox Signal. 2002, 4:391-403.
396. Virmani A., Gaetani F., Binienda Z., Xu A., Duhart H., Ali S.F. Role of mitochondrial dysfunction in neurotoxicity of MPP+: partial protection of PC12 cells by acetyl-L-carnitine. Ann. N. Y. Acad. Sci. 2004, 1025:267-273.
397. Steffen V., Santiago M., de la Cruz C.P., Revilla E., Machado A., Cano J. Effect of intraventricular injection of 1-methyl-4-phenylpyridinium: protection by acetyl-L-carnitine. Hum. Exp. Toxicol. 1995, 14:865-871.
398. Zhu X.P., Sato E.F., Wang Y., Nakamura H., Yodoi J., Inoue M. Acetyl-L-carnitine suppresses apoptosis of thioredoxin 2-deficient DT40 cells. Arch. Biochem. Biophys. 2008, 478:154-160.
399. Di Cesare Mannelli L., Ghelardini C., Calvani M., Nicolai R., Mosconi L., Vivoli E., Pacini A., Bartolini A. Protective effect of acetyl-L-carnitine on the apoptotic pathway of peripheral neuropathy. Eur. J. Neurosci. 2007, 26:820-827.
400. Cassano P., Sciancalepore A.G., Pesce V., Flück M., Hoppeler H., Calvani M., Mosconi L., Cantatore P., Gadaleta M.N. Acetyl-L-carnitine feeding to unloaded rats triggers in soleus muscle the coordinated expression of genes involved in mitochondrial biogenesis. Biochim. Biophys. Acta 2006, 1757:1421-1428.
401. Traina G., Valleggi S., Bernardi R., Rizzo M., Calvani M., Nicolai R., Mosconi L., Durante M., Brunelli M. Identification of differentially expressed genes induced in the rat brain by acetyl-L-carnitine as evidenced by suppression subtractive hybridization. Brain Res. Mol. Brain Res. 2004, 132:57-63.
402. Traina G., Bernardi R., Cataldo E., Macchi M., Durante M., Brunelli M. In the rat brain acetyl-L-carnitine treatment modulates the expression of genes involved in neuronal ceroid lipofuscinosis. Mol. Neurobiol. 2008, 38:146-152.
403. Traina G., Federighi G., Brunelli M. Up-regulation of kinesin light-chain 1 gene expression by acetyl-L-carnitine: therapeutic possibility in Alzheimer's disease. Neurochem. Int. 2008, 53:244-247.
404. Traina G., Federighi G., Brunelli M., Scuri R. Cytoprotective effect of acetyl-L-carnitine evidenced by analysis of gene expression in the rat brain. Mol. Neurobiol. 2009, 39:101-106.
405. Lee T.I., Causton H.C., Holstege F.C., Shen W.C., Hannett N., Jennings E.G., Winston F., Green M.R., Young R.A. Redundant roles for the TFIID and SAGA complexes in global transcription. Nature 2000, 405:701-704.
406. Kim D.H., Kim M., Kwon H.J. Histone deacetylase in carcinogenesis and its inhibitors as anti-cancer agents. J. Biochem. Mol. Biol. 2003, 36:110-119.
407. Takahashi H., McCaffery J.M., Irizarry R.A., Boeke J.D. Nucleocytosolic acetyl-coenzyme a synthetase is required for histone acetylation and global transcription. Mol. Cell 2006, 23:207-217.
408. Avruch J., Zhang X.F., Kyriakis J.M. Raf meets Ras: completing the framework of a signal transduction pathway. Trends Biochem. Sci. 1994, 19:279-283.
409. Thorson J.A., Yu L.W., Hsu A.L., Shih N.Y., Graves P.R., Tanner J.W., Allen P.M., Piwnica-Worms H., Shaw A.S. 14-3-3 proteins are required for maintenance of Raf-1 phosphorylation and kinase activity. Mol. Cell. Biol. 1998, 18:5229-5238.
410. Yan W.L., Lerner T.J., Haines J.L., Gusella J.F. Sequence analysis and mapping of a novel human mitochondrial ATP synthase subunit 9 cDNA (ATP5G3). Genomics 1994, 24:375-377.
411. Tanaka M., Nakamura F., Mizokawa S., Matsumura A., Matsumura K., Watanabe Y. Role of acetyl-L-carnitine in the brain: revealed by Bioradiography. Biochem. Biophys. Res. Commun. 2003, 306:1064-1069.
412. Bhaumik S.R., Smith E., Shilatifard A. Covalent modifications of histones during development and disease pathogenesis. Nat. Struct. Mol. Biol. 2007, 14:1008-1016.
413. Schwer B., Bunkenborg J., Verdin R.O., Andersen J.S., Verdin E. Reversible lysine acetylation controls the activity of the mitochondrial enzyme acetyl-CoA synthetase 2. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:10224-10229.
414. Lombard D.B., Alt F.W., Cheng H.L., Bunkenborg J., Streeper R.S., Mostoslavsky R., Kim J., Yancopoulos G., Valenzuela D., Murphy A., Yang Y., Chen Y., Hirschey M.D., Bronson R.T., Haigis M., Guarente L.P., Fareser R.V., Weissman S., Verdin E., Schwer B. Mammalian Sir2 homolog SIRT3 regulates global mitochondrial lysine acetylation. Mol. Cell. Biol. 2007, 27:8807-8814.
415. Haigis M.C., Mostoslavsky R., Haigis K.M., Fahie K., Christodoulou D.C., Murphy A.J., Valenzuela D.M., Yancopoulos G.D., Karow M., Blander G., Wolberger C., Prolla T.A., Weindruch R., Alt F.W., Guarente L. SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic beta cells. Cell 2006, 126:941-954.
416. Ahn B.H., Kim H.S., Song S., Lee I.H., Liu J., Vassilopoulos A., Deng C.X., Finkel T. A role for the mitochondrial deacetylase SIRT3 in regulating energy homeostasis. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:14447-14452.
417. Mateo I., Llorca J., Infante J., Rodríguez-Rodríguez E., Berciano J., Combarros O. Gene-gene interaction between 14-3-3 zeta and butyrylcholinesterase modulates Alzheimer's disease risk. Eur. J. Neurol. 2008, 15:219-222.
418. Gadaleta M.N., Petruzzella V., Renis M., Fracasso F., Cantatore P. Reduced transcription of mitochondrial DNA in the senescent rat. Tissue dependence and effect of L-carnitine. Eur. J. Biochem. 1990, 187:501-506.
419. Paradies G., Ruggiero F.M., Gadaleta M.N., Quagliariello E. The effect of aging and acetyl-L-carnitine on the activity of the phosphate carrier and on the phospholipid composition in rat heart mitochondria. Biochim. Biophys. Acta 1992, 1103:324-326.
420. Paradies G., Ruggiero F.M., Petrosillo G., Gadaleta M.N., Quagliariello E. Effect of aging and acetyl-L-carnitine on the activity of cytochrome oxidase and adenine nucleotide translocase in rat heart mitochondria. FEBS Lett. 1994, 350:213-215.
421. Paradies G., Ruggiero F.M., Petrosillo G., Gadaleta M.N., Quagliariello E. Carnitine-acylcarnitine translocase activity in cardiac mitochondria from aged rats: the effect of acetyl-L-carnitine. Mech. Ageing Dev. 1995, 84:103-112.
422. Pesce V., Fracasso F., Musicco C., Lezza A.M., Cantatore P., Gadaleta M.N. Acetyl-L-carnitine dietary supplementation to old rats increases mitochondrial transcription factor A content in rat hindlimb skeletal muscles. Ann. N. Y. Acad. Sci. 2004, 1019:430-433.
423. Gulewitsch S., Amiradzibi S. Ueber das carnosin, eine neue organische base des fleischextracts. Ber. Dtsch. Chem. Ges. 1900, 33:344-379.
424. Krimberg R. Zur Kenntnis der Extraktivstoffe der muskelin. IV. Mutterlung. Uberdas vorkommen des carnosins, carnitins und methylguanidins im fleisch. Hoppe Seylers Z. Physiol. Chem. 1906, 48:412.
425. Krimberg R. Zur Kenntnis der Extraktivstoffe der muskelin. X. Mitteilung. Uber die identitat des novsains mit dem carnitin. Hoppe Seylers Z. Physiol. Chem. 1908, 55:466.
426. Sale C., Saunders B., Harris R.C. Effect of beta-alanine supplementation on muscle carnosine concentrations and exercise performance. Amino Acids 2010, 39:321-333.
427. Boldyrev A.A., Severin S.E. The histidine-containing dipeptides, carnosine and anserine: distribution, properties and biological significance. Adv. Enzyme Regul. 1990, 30:175-194.
428. De Marchis S., Modena C., Peretto P., Migheli A., Margolis F.L., Fasolo A. Carnosine-related dipeptides in neurons and glia. Biochemistry (Mosc.) 2000, 65:824-833.
429. Maynard L.M., Boissonneault G.A., Chow C.K., Bruckner G.G. High levels of dietary carnosine are associated with increased concentrations of carnosine and histidine in rat soleus muscle. J. Nutr. 2001, 131:287-290.
430. Quinn P.J., Boldyrev A.A., Formazuyk V.E. Carnosine: its properties, functions and potential therapeutic applications. Mol. Aspects Med. 1992, 13:379-444.
431. Bonfanti L., Peretto P., De Marchis S., Fasolo A. Carnosine-related dipeptides in the mammalian brain. Prog. Neurobiol. 1999, 59:333-353.
432. Hipkiss A.R. Glycation, ageing and carnosine: are carnivorous diets beneficial?. Mech. Ageing Dev. 2005, 126:1034-1039.
433. Horning M.S., Blakemore L.J., Trombley P.Q. Endogenous mechanisms of neuroprotection: role of zinc, copper, and carnosine. Brain Res. 2000, 852:56-61.
434. Sakai M., Yoshida M., Karasawa N., Teramura M., Ueda H., Nagatsu I. Carnosine-like immunoreactivity in the primary olfactory neuron of the rat. Experientia 1987, 43:298-300.
435. Gariballa S.E., Sinclair A.J. Carnosine: physiological properties and therapeutic potential. Age Ageing 2000, 29:207-210.
436. Tamaki N., Funatsuka A., Fujimoto S., Hama T. The utilization of carnosine in rats fed on a histidine-free diet and its effect on the levels of tissue histidine and carnosine. J. Nutr. Sci. Vitaminol. (Tokyo) 1984, 30:541-551.
437. Chan W.K., Decker E.A., Chow C.K., Boissonneault G.A. Effect of dietary carnosine on plasma and tissue antioxidant concentrations and on lipid oxidation in rat skeletal muscle. Lipids 1994, 29:461-466.
438. Lenney J.F., Peppers S.C., Kucera-Orallo C.M., George R.P. Characterization of human tissue carnosinase. Biochem. J. 1985, 228:653-660.
439. Ferraris R.P., Diamond J., Kwan W.W. Dietary regulation of intestinal transport of the dipeptide carnosine. Am. J. Physiol. 1988, 255:143-150.
440. Hipkiss A.R., Brownson C. A possible new role for the anti-ageing peptide carnosine. Cell. Mol. Life Sci. 2000, 57:747-753.
441. Decker E.A., Livisay S.A., Zhou S. A re-evaluation of the antioxidant activity of purified carnosine. Biochemistry (Mosc.) 2000, 65:766-770.
442. Hipkiss A.R., Brownson C. Carnosine reacts with protein carbonyl groups: another possible role for the anti-ageing peptide?. Biogerontology 2000, 1:217-223.
443. Kohen R., Yamamoto Y., Cundy K.C., Ames B.N. Antioxidant activity of carnosine, homocarnosine, and anserine present in muscle and brain. Proc. Natl. Acad. Sci. U. S. A. 1988, 85:3175-3179.
444. Boldyrev A.A., Formazyuk V.E., Sergienko V.I. Biological significance of histidine-containing dipeptides with special reference to carnosine: chemistry, distribution, metabolism and medical applications. Sov. Sci. Rev. D Physicochem. Biol. 1994, 264:81-85.
445. Aruoma O.I., Laughton M.J., Halliwell B. Carnosine, homocarnosine and anserine: could they act as antioxidants in vivo?. Biochem. J. 1989, 264:863-869.
446. Boldyrev A.A., Dupin A.M., Pindel E.V., Severin S.E. Antioxidative properties of histidine-containing dipeptides from skeletal muscles of vertebrates. Comp. Biochem. Physiol. B 1988, 89:245-250.
447. Mozdzan M., Szemraj J., Rysz J., Nowak D. Antioxidant properties of carnosine re-evaluated with oxidizing systems involving iron and copper ions. Basic Clin. Pharmacol. Toxicol. 2005, 96:352-360.
448. McFarland G.A., Holliday R. Retardation of the senescence of cultured human diploid fibroblasts by carnosine. Exp. Cell Res. 1994, 212:167-175.
449. Hipkiss A.R. Could carnosine or related structures suppress Alzheimer's disease?. J. Alzheimers Dis. 2007, 11:229-240.
450. Dobrota D., Fedorova T., Stvolinsky S., Babusikova E., Likavcanova K., Drgova A., Strapkova A., Boldyrev A. Carnosine protects the brain of rats and Mongolian gerbils against ischemic injury: after-stroke-effect. Neurochem. Res. 2005, 30:1283-1288.
451. Stvolinsky S., Kukley M., Dobrota D., Mezesova V., Boldyrev A. Carnosine protects rats under global ischemia. Brain Res. Bull. 2000, 53:445-448.
452. Tang S., Arumugam T.V., Cutler R.G., Jo D., Magnus T., Chan S.L., Mughal M.R., Telljohann R.S., Nassar M., Ouyang X., Calderan A., Ruzza P., Guiotto A., Mattson M.P. Neuroprotective actions of a histidine analogue in models of ischemic stroke. J. Neurochem. 2007, 101:729-736.
453. Pubill D., Verdaguer E., Sureda F.X., Camins A., Pallas M., Camarasa J., Escubedo E. Carnosine prevents methamphetamine-induced gliosis but not dopamine terminal loss in rats. Eur. J. Pharmacol. 2002, 448:165-168.
454. Dukic-Stefanovic S., Schinzel R., Riederer P., Munch G. AGES in brain ageing: AGE-inhibitors as neuroprotective and anti-dementia drugs?. Biogerontology 2001, 2:19-34.
455. Preston J.E., Hipkiss A.R., Himsworth D.T., Romero I.A., Abbott J.N. Toxic effects of beta-amyloid(25-35) on immortalised rat brain endothelial cell: protection by carnosine, homocarnosine and beta-alanine. Neurosci. Lett. 1998, 242:105-108.
456. Nakayama M., Takahashi K., Kitamuro T., Yasumoto K., Katayose D., Shirato K., Fujii-Kuriyama Y., Shibahara S. Repression of heme oxygenase-1 by hypoxia in vascular endothelial cells. Biochem. Biophys. Res. Commun. 2000, 271:665-671.
457. Okinaga S., Takahashi K., Takeda K., Yoshizawa M., Fujita H., Sasaki H., Shibahara S. Regulation of human heme oxygenase-1 gene expression under thermal stress. Blood 1996, 87:5074-5084.
458. Takahashi K., Nakayama M., Takeda K., Fujia H., Shibahara S. Suppression of heme oxygenase-1 mRNA expression by interferon-gamma in human glioblastoma cells. J. Neurochem. 1999, 72:2356-2361.
459. Shibahara S. The heme oxygenase dilemma in cellular homeostasis: new insights for the feedback regulation of heme catabolism. Tohoku J. Exp. Med. 2003, 200:167-186.
460. Aldini G., Carini M., Beretta G., Bradamante S., Facino R.M. Carnosine is a quencher of 4-hydroxy-nonenal: through what mechanism of reaction?. Biochem. Biophys. Res. Commun. 2002, 298:699-706.
461. Liu Y., Xu G., Sayre L.M. Carnosine inhibits (E)-4-hydroxy-2-nonenal-induced protein cross-linking: structural characterization of carnosine-HNE adducts. Chem. Res. Toxicol. 2003, 16:1589-1597.
462. Reddy V.P., Garrett M.R., Perry G., Smith M.A. Carnosine: a versatile antioxidant and antiglycating agent. Sci. Aging Knowledge Environ. 2005, 18:12.
463. Hipkiss A.R., Worthington V.C., Himsworth D.T., Herwig W. Protective effects of carnosine against protein modification mediated by malondialdehyde and hypochlorite. Biochim. Biophys. Acta 1998, 1380:46-54.
464. Nagasawa T., Yonekura T., Nishizawa N., Kitts D.D. In vitro and in vivo inhibition of muscle lipid and protein oxidation by carnosine. Mol. Cell. Biochem. 2001, 225:29-34.
465. Kang J.H., Kim K.S. Enhanced oligomerization of the alpha-synuclein mutant by the Cu, Zn-superoxide dismutase and hydrogen peroxide system. Mol. Cells 2003, 15:87-93.
466. Kang J.H., Eum W.S. Enhanced oxidative damage by the familial amyotrophic lateral sclerosis-associated Cu, Zn-superoxide dismutase mutants. Biochim. Biophys. Acta 2000, 1524:162-170.
467. Decker E.A., Ivanov V., Zhu B.Z., Frei B. Inhibition of low-density lipoprotein oxidation by carnosine histidine. J. Agric. Food Chem. 2001, 49:511-516.
468. Smith E.C. The buffering of muscle in rigor; protein, phosphate and carnosine. J. Physiol. 1938, 92:336-343.
469. Stout J.R., Graves B.S., Smith A.E., Hartman M.J., Cramer J.T., Beck T.W., Harris R.C. The effect of beta-alanine supplementation on neuromuscular fatigue in elderly (55-92 Years): a double-blind randomized study. J. Int. Soc. Sports Nutr. 2008, 5:21.
470. Harris R.C., Marlin D.J., Dunnett M., Snow D.H., Hultman E. Muscle buffering capacity and dipeptide content in the thoroughbred horse, greyhound dog and man. Comp. Biochem. Physiol. A Comp. Physiol. 1990, 97:249-251.
471. Hipkiss A.R. Carnosine and protein carbonyl groups: a possible relationship. Biochemistry (Mosc.) 2000, 65:771-778.
472. Hipkiss A.R., Preston J.E., Himsworth D.T., Worthington V.C., Keown M., Michaelis J., Lawrence J., Mateen A., Allende L., Eagles P.A., Abbott N.J. Pluripotent protective effects of carnosine, a naturally occurring dipeptide. Ann. N. Y. Acad. Sci. 1998, 854:37-53.
473. Hipkiss A.R., Chana H. Carnosine protects proteins against methylglyoxal-mediated modifications. Biochem. Biophys. Res. Commun. 1998, 248:28-32.
474. Hipkiss A.R., Michaelis J., Syrris P. Non-enzymatic glycosylation of the dipeptide L-carnosine, a potential anti-protein-cross-linking agent. FEBS Lett. 1995, 371:81-85.
475. Stadtman E.R. Protein oxidation and aging. Science 1992, 257:1220-1224.
476. Brownson C., Hipkiss A.R. Carnosine reacts with a glycated protein. Free Radic. Biol. Med. 2000, 28:1564-1570.
477. Rosenberger R.F. Senescence and the accumulation of abnormal proteins. Mutat. Res. 1991, 256:255-262.
478. Hipkiss A.R. Accumulation of altered proteins and ageing: causes and effects. Exp. Gerontol. 2006, 41:464-473.
479. Schöneich C. Protein modification in aging: an update. Exp. Gerontol. 2006, 41:807-812.
480. Hipkiss A.R. On the enigma of carnosine's anti-ageing actions. Exp. Gerontol. 2009, 44:237-242.
481. McFarland G.A., Holliday R. Further evidence for the rejuvenating effects of the dipeptide L-carnosine on cultured human diploid fibroblasts. Exp. Gerontol. 1999, 34:35-45.
482. Shao L., Li Q.H., Tan Z. L-carnosine reduces telomere damage and shortening rate in cultured normal fibroblasts. Biochem. Biophys. Res. Commun. 2004, 324:931-936.
483. Yuneva M.O., Bulygina E.R., Gallant S.C., Kramarenko G.G., Stvolinsky S.L., Semyonova M.L., Boldyrev A.A. Effect of carnosine on age-induced changes in senescence- accelerated mice. J. Anti Aging Med. 1999, 2:337-342.
484. Son D.O., Satsu H., Kiso Y., Totsuka M., Shimizu M. Inhibitory effect of carnosine on interleukin-8 production in intestinal epithelial cells through translational regulation. Cytokine 2008, 42:265-276.
485. Boldyrev A.A. Protection of proteins from oxidative stress: a new illusion or a novel strategy?. Ann. N. Y. Acad. Sci. 2005, 1057:193-205.
486. Alhamdani M.S., Al-Azzawie H.F., Abbas F.K. Decreased formation of advanced glycation end products in peritoneal fluid by carnosine and related peptides. Perit. Dial. Int. 2007, 27:86-89.
487. Alhamdani M.S., Al-Kassir A.H., Abbas F.K., Jaleel N.A., Al-Taee M.F. Antiglycation and antioxidant effect of carnosine against glucose degradation products in peritoneal mesothelial cells. Nephron Clin. Pract. 2007, 107:26-34.
488. Fontana M., Pinnen F., Lucente G., Pecci L. Prevention of peroxynitrite-dependent damage by carnosine and related sulphonamido pseudodipeptides. Cell. Mol. Life Sci. 2002, 59:546-551.
489. Vinson J.A., Howard T.B. Inhibition of protein glycation and advanced glycation end products by ascorbic acid and other vitamins and nutrients. Nutr. Biochem. 1996, 7:659-663.
490. Seidler N.W. Carnosine prevents the glycation-induced changes in electrophoretic mobility of aspartate aminotransferase. J. Biochem. Mol. Toxicol. 2000, 14:215-220.
491. Hipkiss A.R., Preston J.E., Himswoth D.T., Worthington V.C., Abbot N.J. Protective effects of carnosine against malondialdehyde-induced toxicity towards cultured rat brain endothelial cells. Neurosci. Lett. 1997, 238:135-138.
492. Aldini G., Facino R.M., Beretta G., Carini M. Carnosine and related dipeptides as quenchers of reactive carbonyl species: from structural studies to therapeutic perspectives. Biofactors 2005, 24:77-87.
493. Carini M., Aldini G., Beretta G., Arlandini E., Facino R.M. Acrolein-sequestering ability of endogenous dipeptides: characterization of carnosine and homocarnosine/acrolein adducts by electrospray ionization tandem mass spectrometry. J. Mass Spectrom. 2003, 38:996-1006.
494. Min J.N., Whaley R.A., Sharpless N.E., Lockyer P., Portbury A.L., Patterson C. CHIP deficiency decreases longevity, with accelerated aging phenotypes accompanied by altered protein quality control. Mol. Cell. Biol. 2008, 28:4018-4025.
495. Yun C., Stanhill A., Yang Y., Zhang Y., Haynes C.M., Xu C.F., Neubert T.A., Mor A., Philips M.R., Ron D. Proteasomal adaptation to environmental stress links resistance to proteotoxicity with longevity in Caenorhabditis elegans. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:7094-7099.
496. Bonelli M.A., Desenzani S., Cavallini G., Donati A., Romani A.A., Bergamini E., Borghetti A.F. Low-level caloric restriction rescues proteasome activity and Hsc70 level in liver of aged rats. Biogerontology 2008, 9:1-10.
497. Cuervo A.M. Calorie restriction and aging: the ultimate "cleansing diet". J. Gerontol. A Biol. Sci. Med. Sci. 2008, 63:547-549.
498. Bergamini E., Cavallini G., Donati A., Gori Z. The role of autophagy in aging: its essential part in the anti-aging mechanism of caloric restriction. Ann. N. Y. Acad. Sci. 2007, 1114:69-78.
499. Nicoletti V.G., Santoro A.M., Grasso G., Vagliasindi L.I., Giuffrida M.L., Cuppari C., Purrello V.S., Stella A.M., Rizzarelli E. Carnosine interaction with nitric oxide and astroglial cell protection. J. Neurosci. Res. 2007, 85:2239-2245.
500. Tomonaga S., Tachibana T., Takahashi H., Sato M., Denbow D.M., Furuse M. Nitric oxide involves in carnosine-induced hyperactivity in chicks. Eur. J. Pharmacol. 2005, 524:84-88.
501. Thomas S., Kotamraju S., Zielonka J., Harder D.R., Kalyanaraman B. Hydrogen peroxide induces nitric oxide and proteosome activity in endothelial cells: a bell-shaped signaling response. Free Radic. Biol. Med. 2007, 42:1049-1061.
502. Bharadwaj L.A., Davies G.F., Xavier I.J., Ovsenek N. L-carnosine and verapamil inhibit hypoxia-induced expression of hypoxia inducible factor (HIF-1 alpha) in H9c2 cardiomyoblasts. Pharmacol. Res. 2002, 45:175-181.
503. Bonner A.B., Swann M.E., Marway J.S., Heap L.C., Preedy V.R. Lysosomal and nonlysosomal protease activities of the brain in response to ethanol feeding. Alcohol 1995, 12:505-509.
504. Erjavec N., Larsson L., Grantham J., Nyström T. Accelerated aging and failure to segregate damaged proteins in Sir2 mutants can be suppressed by overproducing the protein aggregation-remodeling factor Hsp104p. Genes Dev. 2007, 21:2410-2421.
505. Odashima M., Otaka M., Jin M., Konishi N., Sato T., Kato S., Matsuhashi T., Nakamura C., Watanabe S. Induction of a 72-kDa heat-shock protein in cultured rat gastric mucosal cells and rat gastric mucosa by zinc L-carnosine. Dig. Dis. Sci. 2002, 47:2799-2804.
506. Odashima M., Otaka M., Jin M., Wada I., Horikawa Y., Matsuhashi T., Ohba R., Hatakeyama N., Oyake J., Watanabe S. Zinc L-carnosine protects colonic mucosal injury through induction of heat shock protein 72 and suppression of NF-kappaB activation. Life Sci. 2006, 79:2245-2250.
507. Ohkawara T., Nishihira J., Nagashima R., Takeda H., Asaka M. Polaprezinc protects human colon cells from oxidative injury induced by hydrogen peroxide: relevant to cytoprotective heat shock proteins. World J. Gastroenterol. 2006, 12:6178-6181.
508. J. Michaelis, A.R. Hipkiss, S. Panagiotopoulos, Method for the treatment of the complications and pathology of diabetes, Approved United States Patent (5, 561,110) 1996.
509. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813-820.
510. Ahmed N. Advanced glycation endproducts-role in pathology of diabetic complications. Diabetes Res. Clin. Pract. 2005, 67:3-21.
511. Hipkiss A.R., Brownson C., Carrier M.J. Carnosine, the anti-ageing, anti-oxidant dipeptide, may react with protein carbonyl groups. Mech. Ageing Dev. 2001, 122:1431-1445.
512. Babizhayev M.A., Deyev A.I., Yermakova V.N., Brikman I.V., Bours J. Lipid peroxidation and cataracts: N-acetylcarnosine as a therapeutic tool to manage age-related cataracts in human and in canine eyes. Drugs R&D 2004, 5:125-139.
513. Babizhayev M.A. Rejuvenation of visual functions in older adult drivers and drivers with cataract during a short-term administration of N-acetylcarnosine lubricant eye drops. Rejuvenation Res. 2004, 7:186-198.
514. Shuvaev V.V., Laffont I., Serot J.M., Fujii J., Taniguchi N., Siest G. Increased protein glycation in cerebrospinal fluid of Alzheimer's disease. Neurobiol. Aging 2001, 22:397-402.
515. Picklo M.J., Montine T.J., Amarnath V., Neely M.D. Carbonyl toxicology and Alzheimer's disease. Toxicol. Appl. Pharmacol. 2002, 184:187-197.
516. Reddy V.P., Obrenovich M.E., Atwood C.S., Perry G., Smith M.A. Involvement of Maillard reactions in Alzheimer disease. Neurotox. Res. 2002, 4:191-209.
517. Hipkiss A.R. Could carnosine be a naturally-occurring scavenger for acrolein and other reactive aldehydes in the brain?. Neurobiol. Aging 2002, 23:645-646.
518. Kikuchi S., Shinpo K., Takeuchi M., Yamagishi S., Makita Z., Sasaki N., Tashiro K. Glycation-a sweet tempter for neuronal death. Brain Res. Brain Res. Rev. 2003, 41:306-323.
519. Ghanbari H.A., Ghanbari K., Harris P.L., Jones P.K., Kubat Z., Castellani R.J., Wolozin B.L., Smith M.A., Perry G. Oxidative damage in cultured human olfactory neurons from Alzheimer's disease patients. Aging Cell 2004, 3:41-44.
520. Ahmed N., Ahmed U., Thornalley P.J., Hager K., Fleischer G., Münch G. Protein glycation, oxidation and nitration adduct residues and free adducts of cerebrospinal fluid in Alzheimer's disease and link to cognitive impairment. J. Neurochem. 2005, 92:255-263.
521. Chen F., Wollmer M.A., Hoerndli F., Münch G., Kuhla B., Rogaev E.I., Tsolaki M., Papassotiropoulos A., Götz J. Role for glyoxalase I in Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:7687-7692.
522. Battah S., Ahmed N., Thornally P.J. Novel anti-glycation therapeutic agents: glyoxylase-1-mimetics. Int. Congr. Ser. 2002, 1245:107-111.
523. R. Di Paola, D. Impellizzeri, A.T. Salinaro, E. Mazzon, F. Bellia, M. Cavallaro, C. Cornelius, G. Vecchio, V. Calabrese, E. Rizzarelli, S. Cuzzocrea, Administration of carnosine in the treatment of acute spinal cord injury, Biochem. Pharmacol. 82 (2011) 1478-1489.
524. Münch G., Mayer S., Michaelis J., Hipkiss A.R., Riederer P., Müller R., Neumann A., Schinzel R., Cunningham A.M. Influence of advanced glycation end-products and AGE-inhibitors on nucleation-dependent polymerization of beta-amyloid peptide. Biochim. Biophys. Acta 1997, 1360:17-29.
525. Kim K.S., Choi S.Y., Kwon H.Y., Won M.H., Kang T.C., Kang J.H. The ceruloplasmin and hydrogen peroxide system induces alpha-synuclein aggregation in vitro. Biochimie 2002, 84:625-631.
526. Miyata T., van Ypersele de Strihou C. Angiotensin II receptor blockers and angiotensin converting enzyme inhibitors: implication of radical scavenging and transition metal chelation in inhibition of advanced glycation end product formation. Arch. Biochem. Biophys. 2003, 419:50-54.
527. Boldyrev A.A., Stvolinsky S.L., Tyulina O.V., Koshelev V.B., Hori N., Carpenter D.O. Biochemical and physiological evidence that carnosine is an endogenous neuroprotector against free radicals. Cell. Mol. Neurobiol. 1997, 17:259-271.
528. Boldyrev A., Song R., Lawrence D., Carpenter D.O. Carnosine protects against excitotoxic cell death independently of effects on reactive oxygen species. Neuroscience 1999, 94:571-577.
529. Boldyrev A., Bulygina E., Leinsoo T., Petrushanko I., Tsubone S., Abe H. Protection of neuronal cells against reactive oxygen species by carnosine and related compounds. Comp. Biochem. Physiol. B Biochem. Mol. Biol. 2004, 137:81-88.
530. Boldyrev A., Fedorova T., Stvolinsky S., Borras C., Sastre J., Vina J. Chemical intervention in senescence-accelerated mice metabolism for modelling neurodegenerative diseases: an overview. Int. Congr. Ser. 2004, 1260:109-115.
531. Boldyrev A.A., Stvolinsky S.L., Fedorova T.N., Suslina Z.A. Carnosine as a natural antioxidant and geroprotector: from molecular mechanisms to clinical trials. Rejuvenation Res. 2010, 13:156-158.
532. Gallant S., Semyonova M., Yuneva M. Carnosine as a potential anti-senescence drug. Biochemistry (Mosc.) 2000, 65:866-868.
533. Chez M.G., Buchanan C.P., Aimonovitch M.C., Becker M., Schaefer K., Black C., Komen J. Double-blind, placebo-controlled study of L-carnosine supplementation in children with autistic spectrum disorders. J. Child Neurol. 2002, 17:833-837.
534. Thiel R., Fowkes S.W. Can cognitive deterioration associated with Down syndrome be reduced?. Med. Hypotheses 2005, 64:524-532.
535. Petroff O.A., Hyder F., Rothman D.L., Mattson R.H. Homocarnosine and seizure control in juvenile myoclonic epilepsy and complex partial seizures. Neurology 2001, 56:709-715.
536. Amorini A.M., Bellia F., Di Pietro V., Giardina B., La Mendola D., Lazzarino G., Sortino S., Tavazzi B., Rizzarelli E., Vecchio G. Synthesis and antioxidant activity of new homocarnosine beta-cyclodextrin conjugates. Eur. J. Med. Chem. 2007, 42:910-920.
537. Bellia F., Amorini A.M., La Mendola D., Vecchio G., Tavazzi B., Giardina B., Di Pietro V., Lazzarino G., Rizzarelli E. New glycosidic derivatives of histidine-containing dipeptides with antioxidant properties and resistant to carnosinase activity. Eur. J. Med. Chem. 2008, 43:373-380.
538. Lanza V., Bellia F., D'Agata R., Grasso G., Rizzarelli E., Vecchio G. New glycoside derivatives of carnosine and analogs resistant to carnosinase hydrolysis: Synthesis and characterization of their copper(II) complexes. J. Inorg. Biochem. 2011, 105:181-188.
539. Harman D. The biologic clock: the mitochondria?. J. Am. Geriatr. Soc. 1972, 20:145-147.
540. Linnane A.W., Takayuki O., Sangkot M., Masashi T. Mitochondrial DNA mutations as an important contributor to ageing and degenerative diseases. Lancet 1989, 333:642-664.
541. Vendelbo M.H., Nair K.S. Mitochondrial longevity pathways. Biochim. Biophys. Acta 2011, 1813:634-644.
542. Calabrese V., Cornelius C., Giuffrida Stella A.M., Calabrese E.J. Cellular stress responses, mitostress and carnitine insufficiencies as critical determinants in aging and neurodegenerative disorders: role of hormesis and vitagenes. Neurochem. Res. 2010, 35:1880-1915.
543. Speakman J.R. Body size, energy metabolism and lifespan. J. Exp. Biol. 2005, 208:1717-1730.
544. Bokov A., Chaudhuri A., Richardson A. The role of oxidative damage and stress in aging. Mech. Ageing Dev. 2004, 125:811-826.
545. Sohal R., Weindruch R. Oxidative stress, caloric restriction, and aging. Science 1996, 273:59-63.